BioLife Solutions (BLFS) 10-K 31 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 16, 2022	Jun. 30, 2021
Document Information [Line Items]
Entity Central Index Key	0000834365
Entity Registrant Name	BIOLIFE SOLUTIONS INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	001-36362
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3076866
Entity Address, Address Line One	3303 MONTE VILLA PARKWAY, SUITE 310
Entity Address, City or Town	BOTHELL
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98021
City Area Code	425
Local Phone Number	402-1400
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	BLFS
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 1,433,451,805
Entity Common Stock, Shares Outstanding		42,094,963
Auditor Name	BDO USA, LLP
Auditor Location	Seattle, Washington
Auditor Firm ID	243

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 69,860	$ 90,403
Restricted cash	10	53
Accounts receivable, trade, net of allowance for doubtful accounts of $275 and $85 as of December 31, 2021 and December 31, 2020, respectively	23,217	8,006
Inventories	28,345	11,602
Prepaid expenses and other current assets	4,427	4,648
Total current assets	125,859	114,712
Assets held for rent, net	9,809	4,705
Property and equipment, net	17,657	10,120
Operating lease right-of-use assets, net	18,705	9,675
Financing lease right-of-use assets, net	440	17
Long-term deposits and other assets	325	230
Investments	4,372	5,872
Total intangible assets, net	152,149	31,049
Goodwill	224,741	58,449
Total assets	554,057	234,829
Current liabilities:
Accounts payable	14,945	3,672
Accrued expenses and other current liabilities	7,142	4,543
Warranty liability	9,398	212
Lease liabilities, operating, current portion	2,758	1,107
Lease liabilities, financing, current portion	149	8
Debt, current portion	862	614
Warrant liability	0	2,780
Contingent consideration, current portion	5,127	2,637
Total current liabilities	40,381	15,573
Contingent consideration, long-term	4,900	4,515
Lease liabilities, operating, long-term	16,466	8,757
Lease liabilities, financing, long-term	291	12
Total long-term debt	6,353	655
Deferred tax liabilities	5,487	0
Other long-term liabilities	42	71
Total liabilities	73,920	29,583
Commitments and Contingencies (Note 11)
Shareholders’ equity:
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of December 31, 2021 and December 31, 2020	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized, 41,817,503 and 33,039,146 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively	42	33
Additional paid-in capital	585,397	302,598
Accumulated other comprehensive loss, net of taxes	(282)	0
Accumulated deficit	(105,020)	(97,385)
Total shareholders’ equity	480,137	205,246
Total liabilities and shareholders’ equity	$ 554,057	$ 234,829

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accounts receivable, allowance for doubtful accounts	$ 275	$ 85
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	41,817,503	33,039,146
Common stock, outstanding (in shares)	41,817,503	33,039,146
Series A Preferred Stock [Member]
Preferred stock, shares designated (in shares)	4,250	4,250
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021		Dec. 31, 2020		Dec. 31, 2019
Revenue	$ 119,156	[1]	$ 48,087	[2]	$ 27,371	[3]
Costs and operating expenses:
Research and development	11,821		6,720		3,168
Sales and marketing	14,006		6,413		4,701
General and administrative	32,448		14,607		8,893
Intangible asset amortization	8,202		3,033		1,079
Acquisition costs	1,636		668		940
Change in fair value of contingent consideration	2,875		1,575		50
Total operating expenses	153,096		53,662		27,591
Operating loss	(33,940)		(5,575)		(220)
Other income (expense):
Change in fair value of warrant liability	(121)		3,601		(12,835)
Change in fair value of investments	0		1,319		0
Interest (expense) income, net	(432)		58		501
Other income (expense)	289		0		(13)
Total other income (expense), net	6,187		4,978		(2,978)
Loss before income tax benefit	(27,753)		(597)		(3,198)
Income tax benefit	20,118		3,264		1,541
Net (loss) income	(7,635)		2,667		(1,657)
Net (loss) income attributable to common shareholders:
Basic	(7,635)		2,450		(1,657)
Diluted	$ (7,635)		$ (954)		$ (1,657)
Basic (in dollars per share)	$ (0.20)		$ 0.09		$ (0.09)
Diluted (in dollars per share)	$ (0.20)		$ (0.03)		$ (0.09)
Weighted average shares used to compute (loss) earnings per share attributable to common shareholders:
Basic and Diluted (in shares)	38,503,944		27,306,258		19,460,299
SAVSU [Member]
Other income (expense):
Gain on acquisition	$ 0		$ 0		$ 10,108
Sexton Biotechnologies, Inc. [Member]
Other income (expense):
Gain on acquisition	6,451		0		0
SAVSU [Member]
Other income (expense):
Loss from equity-method investment in SAVSU	0		0		(739)
Product [Member]
Revenue	101,913		44,540		26,844
Costs and operating expenses:
Cost of goods and services	69,676		18,058		8,355
Service Revenue [Member]
Revenue	9,817		1,752		0
Costs and operating expenses:
Cost of goods and services	5,381		1,367		405
Rental Revenue [Member]
Revenue	7,426		1,795		527
Costs and operating expenses:
Cost of goods and services	$ 7,051		$ 1,221		$ 0
[1]	2021 revenue includes product revenue related to Global Cooling from May 3, 2021 through December 31, 2021 and product revenue related to Sexton from September 1, 2021 through December 31, 2021.
[2]	2020 revenue includes service revenue related to SciSafe from October 1, 2020 through December 31, 2020.
[3]	2019 revenue includes product revenue related to Astero Bio Corporation ("Astero") from April 1, 2019 through December 31, 2019; rental revenue related to SAVSU from August 8, 2019 through December 31, 2019; and product revenue related to CBS from November 12, 2019 through December 31, 2019.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net (loss) income	$ (7,635)	$ 2,667	$ (1,657)
Other comprehensive loss - foreign currency translation adjustment, net of tax	(282)	0	0
Comprehensive (loss) income	$ (7,917)	$ 2,667	$ (1,657)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	GCI Acquisition [Member]Common Stock [Member]	GCI Acquisition [Member]Additional Paid-in Capital [Member]	GCI Acquisition [Member]	Sexton Acquisition [Member]Common Stock [Member]	Sexton Acquisition [Member]Additional Paid-in Capital [Member]	Sexton Acquisition [Member]	Preferred Stock [Member]Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018							0	18,547,406
Balance at Dec. 31, 2018							$ 0	$ 19	$ 113,008		$ (98,395)	$ 14,632
Stock based compensation									3,043			3,043
Shares issued in acquisitions (in shares)							0	1,334,219
Shares issued in acquisitions							$ 0	$ 1	23,931	$ 0	0	23,932
Stock option exercises							$ 0	$ 1	1,180	0	0	1,181
Stock option exercises (in shares)								697,010
Stock issued – on vested RSAs (in shares)							0	125,817
Stock issued – on vested RSAs							$ 0	$ 0	0	0	0	0
Warrant exercises (in shares)								121,000
Warrant exercises									2,323			2,323
Net (loss) income							0	$ 0	0	0	(1,657)	(1,657)
Balance (in shares) at Dec. 31, 2019								20,825,452
Balance at Dec. 31, 2019								$ 21	143,485	0	(100,052)	43,454
Stock based compensation							$ 0	$ 0	5,981	0	0	5,981
Shares issued in acquisitions (in shares)							0	611,683
Shares issued in acquisitions							$ 0	$ 0	17,916	0	0	17,916
Stock option exercises							$ 0	$ 1	1,471	0	0	1,472
Stock option exercises (in shares)							0	777,496
Stock issued – on vested RSAs (in shares)							0	208,858
Stock issued – on vested RSAs							$ 0	$ 0	0	0	0	0
Warrant exercises (in shares)							0	8,500
Warrant exercises							$ 0	$ 0	150	0	0	150
Net (loss) income											2,667	2,667
Stock issued as 2019 bonus payout									314			314
Sale of common stock, net of costs (in shares)							0	7,856,012
Sale of common stock, net of costs							$ 0	$ 8	100,113	0	0	100,121
Common stock issued for services (in shares)								3,175
Common stock issued for services									60			60
Cashless exercises of warrants							$ 0	$ 3	33,108	0	0	33,111
Cashless exercises of warrants (in shares)								2,747,970
Balance (in shares) at Dec. 31, 2020							0	33,039,146
Balance at Dec. 31, 2020							$ 0	$ 33	302,598	0	(97,385)	205,246
Stock based compensation							0	0	13,956	0	0	13,956
Shares issued in acquisitions (in shares)	6,636,470			530,502
Shares issued in acquisitions	$ 7	$ 232,734	$ 232,741		$ 31,977	$ 31,977
Stock option exercises							$ 0	$ 1	1,417	0	0	1,418
Stock option exercises (in shares)							0	869,065
Stock issued – on vested RSAs (in shares)							0	672,290
Stock issued – on vested RSAs							$ 0	$ 1	0	0	0	1
Net (loss) income							$ 0	0	0	0	(7,635)	(7,635)
Cashless exercises of warrants								$ 0	2,901			2,901
Cashless exercises of warrants (in shares)								70,030
Fees incurred for registration filings									(186)			(186)
Foreign currency translation										(282)		(282)
Balance (in shares) at Dec. 31, 2021							0	41,817,503
Balance at Dec. 31, 2021							$ 0	$ 42	$ 585,397	$ (282)	$ (105,020)	$ 480,137

Consolidated Statements of Sh_2

Consolidated Statements of Shareholders' Equity (Parentheticals) - shares	May 14, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
WAVI Holding AG and Taurus4757 GmbH Warrants [Member]
Cashless warrant exercises (in shares)	3,871,405	79,100	3,871,405
Cashless warrant exercises (in shares)		79,100	3,879,905	121,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net (loss) income	$ (7,635,000)	$ 2,667,000	$ (1,657,000)
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities
Depreciation	4,663,000	2,035,000	718,000
Amortization of intangible assets	8,202,000	3,033,000	1,079,000
Amortization of loan costs	121,000	0	0
Stock-based compensation	13,956,000	5,981,000	3,043,000
Non-cash lease expense	2,053,000	737,000	512,000
Gain on acquisition of SAVSU	(6,451,000)	0	0
Deferred income tax benefit	(20,127,000)	(3,297,000)	(1,541,000)
Change in fair value of contingent consideration	2,875,000	1,575,000	50,000
Change in fair value of warrant liability	121,000	(3,601,000)	12,835,000
Change in fair value of investments	0	(1,319,000)	0
Stock issued for services	0	60,000	0
Loss on disposal of assets held for rent, net	609,000	365,000	0
Loss on disposal of property and equipment, net	482,000	0	0
Forgiveness of loans payable	(284,000)	0	0
Other	353,000	190,000	15,000
Change in operating assets and liabilities, net of effects of acquisitions
Accounts receivable, trade, net	(10,132,000)	(1,786,000)	(290,000)
Inventories	114,000	(629,000)	(3,777,000)
Prepaid expenses and other current assets	2,802,000	25,000	(704,000)
Accounts payable	2,018,000	(171,000)	768,000
Accrued expenses and other current liabilities	(3,936,000)	780,000	(327,000)
Warranty liability	5,833,000	0	0
Other	(230,000)	0	(142,000)
Net cash (used in) provided by operating activities	(4,593,000)	6,645,000	1,213,000
Cash flows from investing activities
Purchases of property and equipment	(8,385,000)	(1,961,000)	(675,000)
Deposits on property and equipment	0	(2,672,000)	0
Purchases of assets held for rent	(6,371,000)	(2,813,000)	(1,655,000)
Deposits on assets held for rent	0	(362,000)	0
Proceeds from sale of equipment	5,000	35,000	0
Net cash used in investing activities	(13,192,000)	(24,715,000)	(27,018,000)
Cash flows from financing activities
Payments of contingent consideration	0	(483,000)	0
Proceeds from sale of common stock, net of $6.2 million of costs in 2020	0	100,121,000	0
Fees paid related to issuance of common stock	(145,000)	(6,200,000)
Proceeds from line of credit	27,306,000	0	0
Payments on line of credit	(31,536,000)	0	0
Proceeds from exercise of common stock options	1,418,000	1,472,000	1,181,000
Proceeds from exercise of warrants	0	40,000	574,000
Other	(124,000)	(56,000)	(159,000)
Net cash (used in) provided by financing activities	(2,778,000)	102,078,000	1,596,000
Net (decrease) increase in cash, cash equivalents, and restricted cash	(20,563,000)	84,008,000	(24,209,000)
Cash, cash equivalents, and restricted cash – beginning of period	90,456,000	6,448,000	30,657,000
Effects of currency translation on cash, cash equivalents, and restricted cash	(23,000)	0	0
Cash, cash equivalents, and restricted cash – end of period	69,870,000	90,456,000	6,448,000
Non-cash investing and financing activities
Cashless exercise of warrants reclassified from warrant liability to common stock	2,901,000	33,111,000	0
Stock issued as consideration to acquire Global Cooling, Inc. and Sexton Biotechnologies, Inc.	264,718,000	0	0
Equipment acquired under operating leases	6,875,000	8,096,000	0
Equipment acquired under finance leases	440,000	0	0
Purchase of property and equipment not yet paid	197,000	0	29,000
Reclassification of warrant liabilities to equity upon exercise	0	110,000	1,749,000
Cash interest paid	452,000	0	0
Bonus Consideration [Member]
Non-cash investing and financing activities
Stock issued as bonus consideration	0	314,000	0
Paycheck Protection Program CARES Act [Member]
Cash flows from financing activities
Proceeds from Loan	0	2,175,000	0
Payoff of PPP Loan	0	(2,175,000)	0
Equipment Loans [Member]
Cash flows from financing activities
Proceeds from Loan	1,550,000	984,000	0
Payoff of PPP Loan	(214,000)	0	0
Financed Insurance Premium [Member]
Cash flows from financing activities
Payments on financed insurance premium	(1,033,000)	0	0
SAVSU [Member]
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities
Gain on acquisition of SAVSU	0	0	(10,108,000)
Cash flows from investing activities
Cash acquired in acquisition	0	0	1,251,000
Non-cash investing and financing activities
Stock issued as consideration to acquire Global Cooling, Inc. and Sexton Biotechnologies, Inc.	0	0	19,932,000
Astero [Member]
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities
Change in fair value of contingent consideration	(81,000)
Cash flows from investing activities
Payments to Acquire Businesses, Net of Cash Acquired, Total	0	0	(12,439,000)
CBS Acquisition [Member]
Cash flows from investing activities
Payments to Acquire Businesses, Net of Cash Acquired, Total	0	0	(11,000,000)
Cash flows from financing activities
Payments of contingent consideration	0	0
Non-cash investing and financing activities
Stock issued as consideration to acquire Global Cooling, Inc. and Sexton Biotechnologies, Inc.	0	0	4,000,000
SciSafe [Member]
Cash flows from investing activities
Payments to Acquire Businesses, Net of Cash Acquired, Total		(14,947,000)	0
Non-cash investing and financing activities
Stock issued as consideration to acquire Global Cooling, Inc. and Sexton Biotechnologies, Inc.	0	17,916,000	0
Sexton Acquisition [Member]
Cash flows from investing activities
Cash acquired in acquisition	1,559,000
SAVSU Investment [Member]
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities
Loss from equity method investment in SAVSU	0	0	739,000
Sexton Biotechnologies, Inc. [Member]
Cash flows from investing activities
Investment	0	0	(1,500,000)
IVexSol Convertible Debt Investment [Member]
Cash flows from investing activities
Investment in iVexSol convertible debt	0	0	(1,000,000)
IVexSol Preferred Stock Investment [Member]
Cash flows from investing activities
Investment	0	(1,000,000)	0
PanTHERA Cryosolutions Investment [Member]
Cash flows from investing activities
Investment	$ 0	$ (995,000)	$ 0

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stock issuance costs	$ 145	$ 6,200

Note 1 - Organization and Signi

Note 1 - Organization and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. Organization and significant accounting policies Business BioLife Solutions, Inc. (“BioLife”, “us”, “we”, “our”, or the “Company”) is a developer, manufacturer, and supplier of a portfolio of bioproduction tools and services including proprietary biopreservation media, automated thawing devices, cloud-connected shipping containers, ultra-low temperature mechanical freezers, cryogenic and controlled rate freezers and biological and pharmaceutical materials storage. Our CryoStor® freeze media and HypoThermosol® hypothermic storage media are optimized to preserve cells in the regenerative medicine market. These novel biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our Sexton cell processing product line includes human platelet lysates (“hPL”) for cell expansion reducing risk and improving downstream performance over fetal bovine serum, human serum, and other chemically defined media, CellSeal® cryogenic vials that are purpose-built rigid containers used in cell and gene therapy (“CGT”) that can be filled manually or with high throughput systems, and automated cell processing machines that bring multiple processes traditionally performed by manual techniques under a higher level of control to protect therapies from loss or contamination. Our ThawSTAR® product line is comprised of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. These products help administer temperature-sensitive biologic therapies to patients by standardizing the thawing process and reducing the risks of contamination and overheating, which are inherent with the use of traditional water baths. Our cryogenic freezer technology provides for controlled rate freezing and cryogenic storage of biologic materials. Our ultra-low temperature mechanical freezers allow biological materials and vaccines to be stored at temperatures which range from negative 20℃ 86℃. Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions by management affect the Company’s allowance for doubtful accounts, the net realizable value of inventory, fair value of warrant liability, valuation of market based awards, valuations and purchase price allocations related to investments and business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, share-based compensation, contingent consideration from business combinations, and the recoverability of the Company’s deferred tax assets and the related valuation allowance. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Basis of presentation The Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU” acquired on August 8, 2019), November 12, 2019), October 1, 2020), May 3, 2021), September 1, 2021). All long-lived assets are maintained in the United States of America and the Netherlands. Financial statement reclassification Certain classifications on the Consolidated Balance Sheets related to accrued expenses and other current liabilities, debt, current portion, and debt, long-term as of December 31, 2020 no Foreign currency translation The Company translates balance sheet and income statement items into U.S. dollars. For the Company’s subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using quarterly exchange rates which approximate to average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of accumulated other comprehensive (loss) income in shareholders' equity. Segment reporting The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one one Revenue recognition To determine revenue recognition for contractual arrangements that we determine are within the scope of Financial Accounting Standards Board (“FASB”) Topic 606, Revenue from Contracts with Customers five five may not 30 90 December 31, 2021, The Company primarily recognizes product revenues, service revenues, and rental revenues. Product revenues are generated from the sale of biopreservation media, ThawSTAR, and freezer products. We recognize product revenue, including shipping and handling charges billed to customers, at a point in time when we transfer control of our products to our customers, which is upon shipment for substantially all transactions. Shipping and handling costs are classified as part of cost of product revenue in the Consolidated Statement of Operations. Service revenues are generated from the storage of biological and pharmaceutical materials. We recognize service revenues over time as services are performed or ratably over the contract term. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606 10 32 18, not one None December 31, 2021. The Company also generates revenue from the leasing of our property, plant, and equipment, operating right-of-use assets, and evo cold chain systems to customers pursuant to service contracts or rental arrangements entered into with the customer. Revenue from these arrangements is not 606 842, Lease The Company enters into various customer service agreements (collectively, “Service Contracts”) with customers to provide biological and pharmaceutical storage services. In certain of these Service Contracts, the property, plant, and equipment or operating right-of-use assets used to store the customer product are used only for the benefit of one may not The Company has assessed its Service Contracts and concluded that certain of the contracts for the storage of customer products met the criteria to be considered a leasing arrangement (“Embedded Leases”), with the Company as the lessor. The specific Service Contracts that met the criteria were those that provided a single customer with the ability to substantially direct the use of the Company’s property, plant, and equipment or operating right-of-use assets. Under ASC 842, None None Embedded Leases may Total bioproduction tools and services revenue for the years ended December 31, 2021, 2020, 2019 Year Ended December 31, (In thousands, except percentages) 2021 2020 2019 Product revenue Freezer and thaw $ 56,620 $ 13,548 $ 3,312 Cell processing 44,965 30,946 23,367 Storage and cold chain services 328 46 165 Service revenue Storage and cold chain services 9,817 1,752 - Rental revenue Storage and cold chain services 7,426 1,795 527 Total revenue $ 119,156 $ 48,087 $ 27,371 ( 1 2021 May 3, 2021 December 31, 2021 September 1, 2021 December 31, 2021. ( 2 2020 October 1, 2020 December 31, 2020. ( 3 2019 April 1, 2019 December 31, 2019; August 8, 2019 December 31, 2019; November 12, 2019 December 31, 2019. The following table includes estimated rental revenue expected to be recognized in the future related to embedded leases as well as estimated service revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting periods. The Company is electing not one 2014 09, Revenue from Contracts with Customers not one December 31, 2021. The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts: Year Ending December 31, (In thousands) 2022 2023 2024 Total Rental revenue $ 10,151 $ 3,748 $ 900 $ 14,799 Service revenue $ 67 $ 31 $ 10 $ 108 Risks and uncertainties COVID- 19 Our domestic and international operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID- 19” December 31, 2021, In the year ended December 31, 2021, 19 not 19 19. The Company reviews capital and amortizing intangible assets (long-lived assets) for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount may not 19 June 30, 2020 19. As a result of the Company’s outlook for revenue from the ThawSTAR and freezer product lines, estimated undiscounted cash flow projections were developed to determine if any impairment of the related intangible assets was warranted. After conducting such review, the Company determined that there was no June 30, 2020. 19 The Company revised the revenue projections for the ThawSTAR and freezer product lines in the second June 30, 2020 December 31, 2020 two no December 31, 2020. June 30, 2020, December 31, 2020 December 31, 2020. The Company may 19 third Any disruption and volatility in the global capital markets as a result of the pandemic may 19 not The ultimate extent to which the COVID- 19 19 On March 27, 2020, On March 11, 2021, 2021” We determined that we met the original eligibility requirements per the guidelines original established by the U.S. federal government as part of the CARES Act for the Pursuant to the Paycheck Protection Program (the “PPP”). As such, on April 20, 2020, April 29, 2020. March 30, 2020, December 31, 2021, December 31, 2021, December 31, 2022. In the SciSafe acquisition, the Company acquired a $295,300 loan from the PPP. The loan incurred interest at 1% and was unsecured. Of the principal borrowed, $284,000 was forgiven in December 2021. not December 2021. Earnings per share The Company considers its unexercised warrants and unvested restricted shares, which contain non-forfeitable rights to dividends, participating securities, and includes such participating securities in its computation of earnings per share pursuant to the two two two The following table presents computations of basic and diluted earnings per share under the two Year Ended December 31, (In thousands, except share and earnings per share data) 2021 2020 2019 Basic earnings (loss) per common share Numerator: Net (loss) income $ (7,635 ) $ 2,667 $ (1,657 ) Amount attributable to unvested restricted shares - (135 ) - Amount attributable to warrants outstanding - (82 ) - Net (loss) income allocated to common shareholders (7,635 ) 2,450 (1,657 ) Denominator: Weighted-average common shares issued and outstanding 38,503,944 27,306,258 19,460,299 Basic (loss) earnings per common share $ (0.20 ) $ 0.09 $ (0.09 ) Diluted earnings (loss) per common share Numerator: Net (loss) income $ (7,635 ) $ 2,667 $ (1,657 ) Amount attributable to warrants - (20 ) - Less: gain related to change in fair value of warrants - (3,601 ) - Diluted (loss) earnings per common share (7,635 ) (954 ) (1,657 ) Denominator: Weighted-average common shares issued and outstanding 38,503,944 27,306,258 19,460,299 Diluted (loss) earnings per common share $ (0.20 ) $ (0.03 ) $ (0.09 ) The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: Year Ended December 31, 2021 2020 2019 Stock options and restricted stock awards 1,637,745 2,131,794 2,564,456 Warrants 18,204 1,499,953 2,956,039 Total 1,655,949 3,631,747 5,520,495 Cash, cash equivalents, and restricted cash Cash equivalents consist primarily of interest-bearing money market accounts. We consider all highly liquid debt instruments purchased with an initial maturity of three may not Restricted cash consists entirely of amounts that will be recovered from escrow in relation to the acquisition of SciSafe. The restricted cash is short term in nature, as the Company anticipates to receive the funds within one The following is a summary of the Company’s cash, cash equivalents, and restricted cash total as presented in the Company’s consolidated statements of cash flows for the years ended December 31, 2021, 2020, 2019. Year Ended December 31, (In thousands) 2021 2020 2019 Cash and cash equivalents $ 69,860 $ 90,403 $ 6,448 Restricted cash 10 53 - Total cash, cash equivalents, and restricted cash $ 69,870 $ 90,456 $ 6,448 Inventories Inventories relate to the Company’s cell and gene therapy products. The Company values biopreservation media inventory at cost or, if lower, net realizable value, using the specific identification method. All other inventory is valued at cost or, if lower, net realizable value, using the first first no Accounts receivable Accounts receivable consist of short-term amounts due from our customers (generally 30 90 Accounts receivable are stated at principal amount, do not Investments We periodically invest in securities of private companies to promote business and strategic objectives. These investments are measured and recorded as follows: Non-marketable equity securities are equity securities without a readily determinable fair value. As of December 31, 2021, 1 2 December 31, 2020, 1 2 As of December 31, 2021, September 1, 2021. December 31, 2020, not September 2019, December 31, 2021, 2020, 2019, November 2020, 1 2 In November 2020, June 2021, first As of December 31, 2021, no Property and equipment Property and equipment are stated at cost and are depreciated using the straight-line method over estimated useful lives of three ten Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not may December 31, 2021, 2020, 2019. Assets held for rent Assets held for rent are carried at cost less accumulated depreciation. These assets consist of dedicated storage space, evo shippers and related components in production shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. Assets utilized to provide dedicated storage space are depreciated over their applicable useful lives once placed in service. Shippers are depreciated over a useful life of three Our customers rent assets per a rental agreement. Each agreement provides for fixed monthly rent. Rental revenue and fees are recognized over the rental term on a straight-line basis. We retain the ownership of the assets rented. At the end of the rental agreement, the customer returns the asset to the Company. Assets held for rent are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not may no December 31, 2021, 2020, 2019. Lease accounting We determine if an arrangement is a lease at inception. Where an arrangement is a lease, we determine if it is an operating lease or a finance lease. At lease commencement, we record a lease liability and corresponding right-of-use (“ROU”) asset. Lease liabilities represent the present value of our future lease payments over the expected lease term which includes options to extend or terminate the lease when it is reasonably certain those options will be exercised. The present value of our lease liability is determined using our incremental collateralized borrowing rate at lease inception. ROU assets represent our right to control the use of the leased asset during the lease and are recognized in an amount equal to the lease liability for leases with an initial term greater than 12 We elected to apply the practical expedient for short-term leases and accordingly do not twelve Warranty Our standard warranty terms typically extend between one seven Income taxes We account for income taxes using an asset and liability method which generally requires recognition of deferred tax assets and liabilities for the expected future tax effects of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are recognized for the future tax effects of differences between tax bases of assets and liabilities, and financial reporting amounts, based upon enacted tax laws and statutory rates applicable to the periods in which the differences are expected to affect taxable income. We evaluate the likelihood of realization of deferred tax assets and provide an allowance where, in management’s opinion, it is more likely than not not We determine any uncertain tax positions based on a determination of whether and how much of a tax benefit taken in the Company’s tax filings or positions is more likely than not Judgment is applied in the determination of the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. As of December 31, 2021, Advertising Advertising costs are expensed as incurred and totaled $552,000, $167,000, and $43,000 for the years ended December 31, 2021, 2020, 2019, Concentrations of risk In the years ended December 31, 2021, 2020, 2019, one No 10% In the year ended December 31, 2019, No 10% December 31, 2021, 2020, 2019. The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Year Ended December 31, Revenue by customers geographic locations 2021 2020 2019 United States 78 % 73 % 69 % Canada 7 % 13 % 16 % Germany 4 % 4 % 3 % Europe, Middle East, Africa (excluding Germany) 10 % 8 % 11 % Other 1 % 2 % 1 % Total revenue 100 % 100 % 100 % The following table represents the Company’s long-lived assets by geographic area as of December 31: (In thousands) 2021 2020 United States $ 40,708 $ 30,389 Netherlands 5,903 - Total $ 46,611 $ 30,389 As of December 31, 2021 2020, two one No 10% As of December 31, 2021 2020, one one No 10% Research and development Research and development costs are expensed as incurred. Stock-based compensation We measure and record compensation expense using the applicable accounting guidance for share-based payments related to stock options, time-based restricted stock, market-based restricted stock awards and performance-based restricted stock awards granted to our directors and employees. The fair value of stock options, including performance awards, without a market-based condition is determined by using the Black-Scholes option-pricing model. The fair value of restricted stock awards with a market condition is estimated at the date of grant using the Monte Carlo Simulation model. The Black-Scholes and Monte Carlo Simulation valuation models incorporate assumptions as to stock price volatility, the expected life of options or awards, a risk-free interest rate and dividend yield. The fair value of restricted stock, including performance awards, without a market condition is estimated using the current market price of our common stock on the date of grant. We expense stock-based compensation for stock options, restricted stock awards, and performance awards over the requisite service period. For awards with only a service condition, we expense stock-based compensation using the straight-line method over the requisite service period for the entire award. For awards with a market condition, we expense the grant date fair value over the vesting period regardless of the value that the award recipients ultimately receive. We have, from time to time, modified the terms of restricted stock awards awarded to employees. We account for the incremental increase in the fair value over the original award on the date of the modification as an expense for vested awards or over the remaining service (vesting) period for unvested awards. The incremental compensation cost is the excess of the fair value of the modified award on the date of modification over the fair value of the original award immediately before the modification. Business combinations, goodwill and intangible assets Business combinations The Company accounts for business acquisitions using the acquisition method as required by FASB ASC Topic 805, Business Combinations The Company’s identifiable assets acquired and liabilities, including identified intangible assets, assumed in a business combination are recorded at their acquisition date fair values. The valuation requires management to make significant estimates and assumptions, especially with respect to long-lived and intangible assets. Critical estimates in valuing intangible assets include, but are not ● future expected cash flows, including revenue and expense projections; ● discount rates to determine the present value of recognized assets and liabilities and; ● revenue volatility to determine contingent consideration using option pricing models Goodwill is calculated as the excess of the acquisition price over the fair value of net assets acquired, including the amount assigned to identifiable intangible assets. Acquisition-related costs, including advisory, legal, accounting, valuation, and other costs, are expensed in the periods in which these costs are incurred. The results of operations of an acquired business are included in the consolidated financial statements beginning at the acquisition date. The Company estimates the acquisition date fair value of the acquisition-related contingent consideration using various valuation approaches, including option pricing models, as well as significant unobservable inputs, reflecting the Company’s assessment of the assumptions market participants would use to value these liabilities. The fair value of the contingent consideration is remeasured each reporting period. During the measurement period, which may one Goodwill Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. Goodwill is not fourth may first not 350, Intangibles Goodwill and Other not 50 not not not not one fourth 2021. no Intangible assets Intangible assets with a definite life are amortized over their estimated useful lives using the straight-line method and the amortization expense is recorded within intangible asset amortization in the Consolidated Statements of Operations. If the estimate of a definite-lived intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. Definite-lived intangible assets and their related estimated useful lives are reviewed at least annually to determine if any adverse conditions exist that would indicate the carrying value of these assets may not no may not Indefinite-lived intangibles are carried at the initially recorded fair value less any recognized impairment. In-process research and development (“IPR&D”) is initially capitalized at fair value as an intangible asset with an indefinite life. When the IPR&D project is complete, it is reclassified as a definite-lived intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, a charge would be recorded for the value of the related intangible asset to our Consolidated Statement of Operations in the period it is abandoned. Indefinite-lived intangibles are tested annually for impairment. Impairment assessments are conducted more frequently if certain conditions exist, including a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for the Company’s products or changes in the size of the market for the Company’s products. If impairment indicators are present, the Company determines whether the underlying intangible asset is recoverable through estimated future undiscounted cash flows. If the asset is not one 2021 fourth 2021 no 2021 no Certain warrants which have features that may Warrants that include cash settlement features are recorded as liabilities at their estimated fair value at the date of issuance and are remeasured at fair value each reporting period with the increase or decrease in fair value recorded in the Consolidated Statements of Operations. The warrants are measured at estimated fair value using the Black Scholes valuation model, which is based, in part, upon inputs for which there is little or no zero December 31, 2021, no December 31: 2020 2019 Risk free interest rate 0.1 % 1.9 % Expected dividend yield 0.0 % 0.0 % Contractual remaining lives 0.2 1.7 Expected volatility 56.8 % 70.3 % Recent accounting pronouncements In November 2021, No. 2021 10, Government Assistance (Topic 832 December 15, 2023, In October 2021, No. 2021 08, Business Combinations (Topic 805 Accounting for Contract Assets and Contract Liabilities from Contracts with Customers Revenue from Contracts with Customers (Topic 606 606 2021 08 December 15, 2022, In July 2021, No. 2021 05, Leases (Topic 842 2021 05 840. not 1 842 10 25 2 25 3; 2 one 2021 05 December 15, 2021, not In May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04 2021 04 December 15, 2021, 2021 04 not In August 2020, No. 2020 06, Debt - Debt with Conversion and Other Options (Subtopic 470 20 s Own Equity (Subtopic 815 40 2020 06 2020 06 2020 06 December 15, 2021, no December 15, 2020. not In March 2020, No. 2020 04, Reference Rate Reform (Topic 848 2020 04 January 2021, 2021 01, no December 1, 2022, not In June 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13 November 19, 2019, 2016 13 December 15, 2023,

Note 2 - Fair Value Measurement

Note 2 - Fair Value Measurement	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	2. Fair value measurement In accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures 820” 2 820 820 three Level 1 Level 2 1 not Level 3 For the investment in iVexSol convertible debt that was converted to Series A- 1 November 2020, 3 September 2019 The fair value of the Astero contingent consideration liability was initially valued based on unobservable inputs using a Black-Scholes valuation model. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 17.5%, risk-free rates between 2.29% and 2.41% and revenue volatility of 56%. Significant increases (decreases) in any of those inputs in isolation would result in a significantly higher (lower) fair value measurement. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the contingent consideration having a maximum payout amount, changes in these assumptions would not December 31, 2021, December 31, 2021. December 31, 2020 $81,000. The fair value of the CBS contingent consideration liability was initially valued based on unobservable inputs using a Monte Carlo simulation. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 26.0%, a risk-free rate of approximately 1.74% and revenue volatility of 70%. Significant increases (decreases) in any of those inputs in isolation would result in a significantly higher (lower) fair value measurement. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the contingent consideration having a maximum payout amount, changes in these assumptions would not December 31, 2021, December 31, 2021 2020 The fair value of the SciSafe contingent consideration liability was initially valued based on unobservable inputs using a Monte Carlo simulation. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 4.5%, a risk-free rate of approximately 0.20%, asset volatility of 60%, and revenue volatility of 15%. Significant increases (decreases) in any of those inputs in isolation would result in a significantly higher (lower) fair value measurement. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the contingent consideration having a maximum payout amount, changes in these assumptions would not December 31, 2021, December 31, 2021 2020 December 31, 2021 2020, For the warrant liability, the significant Level 3 March 25, 2021. December 31, 2020, not March 25, 2021, There were no December 31, 2021 not The following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 2020, three (In thousands) As of December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 63,873 $ - $ - $ 63,873 Total 63,873 - - 63,873 Liabilities: Contingent consideration - business combinations - - 10,027 10,027 Total $ - $ - $ 10,027 $ 10,027 As of December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 90,403 $ - $ - $ 90,403 Total 90,403 - - 90,403 Liabilities: Contingent consideration - business combinations - - 7,152 7,152 Warrant liability - - 2,780 2,780 Total $ - $ - $ 9,932 $ 9,932 The fair values of money market funds classified as Level 1 3 1 Organization and Significant Accounting Policies. no The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 December 31, 2021, 2020, 2019: Year Ended December 31, (In thousands) 2021 2020 2019 Beginning balance $ 7,152 $ 1,914 - Additions - 3,663 2,347 Change in fair value recognized in net (loss) income 2,875 1,575 50 Payments earned, reclassified to accrued liabilities - - (483 ) Ending balance $ 10,027 $ 7,152 $ 1,914 The following table presents the changes in fair value of warrant liabilities which are measured using Level 3 December 31, 2021, 2020, 2019: Year Ended December 31, (In thousands) 2021 2020 2019 Beginning balance $ 2,780 $ 39,602 28,516 Exercised warrants (2,901 ) (33,221 ) (1,749 ) Change in fair value recognized in net (loss) income 121 (3,601 ) 12,835 Ending balance $ - $ 2,780 $ 39,602

Note 3 - Inventories

Note 3 - Inventories	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	3. Inventories Inventories consist of the following as of December 31, 2021 2020: (In thousands) 2021 2020 Raw materials $ 17,252 $ 2,855 Work in progress 5,015 2,006 Finished goods 6,078 6,741 Total $ 28,345 $ 11,602

Note 4 - Assets Held for Rent

Note 4 - Assets Held for Rent	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Assets Held For Rent [Text Block]	4. Assets held for rent Assets held for rent consist of the following as of December 31, 2021 2020: (In thousands) 2021 2020 Shippers placed in service $ 5,645 $ 3,171 Fixed assets held for rent 4,040 - Accumulated depreciation (2,272 ) (411 ) Net 7,413 2,760 Shippers and related components in production 2,396 1,945 Total $ 9,809 $ 4,705 Shippers and related components in production include shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. We recognized $1.9 million, $671,000, and $174,000 in depreciation expense related to assets held for rent during the years ended December 31, 2021, 2020, 2019,

Note 5 - Leases

Note 5 - Leases	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Lessee, Leases [Text Block]	5. Leases We have various operating lease agreements for office space, warehouses, manufacturing, and production locations as well as vehicles and other equipment. Our real estate leases have remaining lease terms of one ten not one five one five Our financing leases relate to research equipment, machinery, and other equipment. The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of December 31, 2021 2020: 2021 2020 Weighted average discount rate - operating leases 3.8 % 3.3 % Weighted average discount rate - finance leases 6.1 % 5.7 % Weighted average remaining lease term in years - operating leases 7.8 9.4 Weighted average remaining lease term in years - finance leases 3.0 2.6 The components of lease expense for the years ended December 31, 2021, 2020, 2019 Year Ended December 31, (In thousands) 2021 2020 2019 Operating lease costs $ 2,817 $ 839 $ 612 Short-term lease costs 1,727 277 51 Total operating lease costs 4,544 1,116 663 Variable lease costs 749 357 299 Total lease expense $ 5,293 $ 1,473 $ 962 Maturities of our lease liabilities as of December 31, 2021 (In thousands) Operating Leases Financing Leases 2022 $ 3,443 $ 171 2023 3,151 171 2024 2,883 101 2025 2,497 37 2026 2,006 2 Thereafter 8,364 - Total lease payments 22,344 482 Less: interest (3,120 ) (42 ) Total present value of lease liabilities $ 19,224 $ 440

Note 6 - Goodwill and Intangibl

Note 6 - Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	6. Goodwill and intangible assets Goodwill The following table represents the changes in the carrying value of goodwill for the years ended December 31, 2021 2020: (In thousands) Goodwill Balance as of December 31, 2019 $ 33,637 Correction of an error related to CBS goodwill (131 ) Goodwill related to SciSafe acquisition 24,943 Balance as of December 31, 2020 58,449 Goodwill related to Global Cooling acquisition 137,822 Goodwill related to Sexton acquisition 28,470 Balance as of December 31, 2021 $ 224,741 We adjusted goodwill from the CBS Acquisition related to an immaterial error of $131,000 in payables that were paid during closing and incorrectly recorded as liabilities in our purchase price accounting as of December 31, 2019. December 31, 2020. Intangible assets Intangible assets, net consisted of the following as of December 31, 2021 2020: (In thousands, except weighted average useful life) December 31, 2021 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 17,516 $ (1,776 ) $ 15,740 10.3 Tradenames 35,574 (2,306 ) 33,268 13.8 Technology - acquired 41,942 (7,789 ) 34,153 5.9 Non-compete agreements 1,990 (442 ) 1,548 3.0 In-process research and development⁽¹⁾ 67,440 - 67,440 N/A Total intangible assets $ 164,462 $ (12,313 ) $ 152,149 9.8 December 31, 2020 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 8,220 $ (330 ) $ 7,890 12.8 Tradenames 6,610 (508 ) 6,102 14.0 Technology - acquired 19,670 (3,232 ) 16,438 7.1 Non-compete agreements 660 (41 ) 619 3.8 Total intangible assets $ 35,160 $ (4,111 ) $ 31,049 9.7 ( 1 In-process R&D represents the fair value of incomplete research and development that has not Amortization expense for finite-lived intangible assets was $8.2 million, $3.0 million, and $1.1 million for the years ended December 31, 2021, 2020, 2019, December 31, 2021, (In thousands) For the Years Ending December 31, Estimated Amortization Expense 2022 $ 11,421 2023 10,951 2024 10,126 2025 9,748 2026 9,346 Thereafter 33,117 Total $ 84,709

Note 7 - Line of Credit and Lon

Note 7 - Line of Credit and Long-term Debt	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Long-term Debt [Text Block]	7. Line of credit and long-term debt Line of credit In May 2021, 3 October 2021, Long-term debt In May 2021, three 3 In October 2021, three one two one three one Long-term debt consisted of the following as of December 31, 2021 2020: December 31, (In thousands) Maturity Date Interest Rate 2021 2020 2022 term loan 1 Sep-24 4.0 % $ 1,750 $ - 2022 term loan 2 Various 4.0 % 2,813 - Insurance premium financing Apr-22 4.0 % 373 - Paycheck Protection Program loan May-22 1.0 % - 295 Freezer equipment loan Dec-25 5.7 % 612 365 Manufacturing equipment loans Oct-25 5.7 % 355 439 Freezer installation loan Various 6.3 % 1,334 156 Other loans Various Various 9 14 Total debt, excluding unamortized debt issuance costs 7,246 1,269 Less: unamortized debt issuance costs (31 ) - Total debt 7,215 1,269 Less: current portion of debt (862 ) (614 ) Total long-term debt $ 6,353 $ 655 The 2022 As of December 31, 2021, five (In thousands) Amount 2022 $ 862 2023 813 2024 2,294 2025 543 2026 221 Thereafter 2,513 Total debt, excluding unamortized debt issuance costs 7,246 Less: unamortized debt issuance costs (31 ) Total debt $ 7,215

Note 8 - Income Taxes

Note 8 - Income Taxes	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	8. Income taxes The following are the domestic and foreign components of the Company's loss before income taxes: Year Ended December 31, (In thousands) 2021 2020 2019 Domestic $ (27,317 ) $ (597 ) $ (3,198 ) Foreign (436 ) - - Total $ (27,753 ) $ (597 ) $ (3,198 ) Income tax benefit consists of the following: Year Ended December 31, (In thousands) 2021 2020 2019 Current: Federal $ - $ - $ - State - 33 - Foreign 9 - - Total current tax provision 9 33 - Deferred: Federal (17,703 ) (3,297 ) (1,541 ) State (2,424 ) - - Foreign - - - Total deferred tax benefit (20,127 ) (3,297 ) (1,541 ) Income tax benefit $ (20,118 ) $ (3,264 ) $ (1,541 ) In the years ended December 31, 2021, 2020, 2019, In connection with the 2021 2021 In connection with the 2020 $3.3 In connection with the 2019 $1.5 A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows: Year Ended December 31, 2021 2020 2019 Federal statutory tax 21 % 21 % 21 % State tax, net of federal benefit 7 % 39 % - Stock compensation 38 % 538 % 74 % Sec. 162(m) limitation on executive compensation (12 %) (35 %) (17 %) Fair value change in contingent consideration (2 %) (81 %) - Fair value change in warrant liability - 127 % (82 %) Transaction costs (1 %) (6 %) (4 %) Gain on stock acquisition 5 % - 64 % Tax credits - 12 % 5 % Change in valuation allowance 21 % 35 % (5 %) Book loss on equity method investment - - (5 %) Expired net operating losses (5 %) (100 %) (5 %) Other - (3 %) 1 % Total 72 % 547 % 47 % The principal components of the Company’s net deferred tax assets are as follows as of December 31, 2021 2020: (In thousands) 2021 2020 Deferred tax assets related to: Net operating loss carryforwards $ 27,500 $ 12,314 Stock-based compensation 2,066 1,678 Accruals and reserves 2,902 427 Inventory 236 142 Lease liabilities 4,198 2,247 Tax credit carryforward 594 225 Other 318 48 Total deferred tax assets 37,814 17,081 Deferred tax liabilities related to: Intangibles (35,241 ) (5,025 ) Right-of-use assets (4,070 ) (2,261 ) Fair value change in investments (294 ) (287 ) Fixed assets (1,203 ) (959 ) Other - (51 ) Total deferred tax liabilities (40,808 ) (8,583 ) Net deferred tax (liabilities) assets before valuation allowance (2,994 ) 8,498 Less: valuation allowance (2,493 ) (8,498 ) Net deferred tax liabilities $ (5,487 ) $ - Realization of deferred tax assets is dependent upon the generation of future taxable income, if any, the timing and amount of which are uncertain. The assessment regarding whether a valuation allowance is required on deferred tax assets considers the evaluation of both positive and negative evidence when concluding whether it is more likely than not December 31, 2021 2020 The changes in the valuation allowance for deferred tax assets were as follows: (In thousands) 2021 2020 2019 Balance at January 1 $ 8,498 $ 8,706 $ 8,345 Deferred tax liabilities assumed through acquisitions (8,498 ) (3,297 ) (1,541 ) Charged to income tax expense 2,493 3,089 1,902 Balance at December 31 $ 2,493 $ 8,498 $ 8,706 As of December 31, 2021, 2023 2037, may The Company determines its uncertain tax positions based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not A reconciliation of the beginning and ending balances of uncertain tax positions in the years ended December 31, 2021 2020 (In thousands) 2021 2020 Balance as of January 1 $ 96 $ - Increase related to prior year tax positions - 36 Increase related to current year tax positions 159 60 Balance as of December 31 $ 255 $ 96 The Company did not December 31, 2019. 2003 2021.

Note 9 - Warrants

Note 9 - Warrants	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Warrants [Text Block]	9. Warrants In March 2014, March 2021. In May 2016, May 2021. In May 2020, Taurus4757 In March 2021, The following table summarizes warrant activity for the years ended December 31, 2021, 2020, 2019: 2021 2020 2019 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Outstanding at beginning of year 79,100 $ 4.75 3,959,005 $ 4.33 4,080,005 $ 4.35 Exercised (79,100 ) 4.75 (3,879,905 ) 4.33 (121,000 ) 4.75 Outstanding and exercisable at end of year - $ - 79,100 $ 4.75 3,959,005 $ 4.33

Note 10 - Stock-based Compensat

Note 10 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	10. Stock-based compensation Stock compensation plans Our stock-based compensation programs are long-term retention programs that are intended to attract, retain and provide incentives for talented employees, officers and directors, and to align stockholder and employee interests. We have the following stock-based compensation plans and programs: During 2013, 2013 “2013 2013 May 2017, July 2020, June 2021, December 31, 2021, 2013 The Company also issued, outside any approved compensation plans, non-incentive stock options. As of December 31, 2021, 2019. Issuance of shares When options and warrants are exercised, it is the Company’s policy to issue new shares. Stock option activity Service vesting-based stock options The following is a summary of service vesting-based stock option activity for the year ended December 31, 2021 2020, December 31, 2021 2020: 2021 2020 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 844,455 $ 2.00 1,570,455 $ 1.96 Exercised (183,064 ) 1.61 - - Forfeited (1,146 ) 5.69 (726,000 ) 1.91 Expired (35,714 ) 1.73 - - Outstanding as of end of year 624,531 $ 2.13 844,455 $ 2.00 Stock options exercisable at year end 624,531 $ 2.13 832,478 $ 1.98 We recognized stock compensation expense related to service-based options of $25,000, $119,000, and $370,000 during the years ended December 31, 2021, 2020, 2019. December 31, 2021, December 31, 2021. December 31, 2021, 2020, 2019 December 31, 2021, 2020, 2019. December 31, 2021 December 31, 2021. The following table summarizes information about service vesting-based stock options outstanding as of December 31, 2021: Range of Exercise Prices Number Outstanding as of December 31, 2021 Weighted Average Remaining Contractual Life Weighted Average Exercise Price $1.00 - 1.50 26,428 1.05 $ 1.38 $1.51 - 2.00 290,760 3.27 1.87 $2.01 - 2.50 265,775 3.35 2.06 $2.51 - 8.60 41,568 3.75 4.86 624,531 3.24 $ 2.13 Performance-based stock options The Company’s Board of Directors implemented a Management Performance Bonus Plan for 2017. December 31, 2017, 2017 not no February 27, 2018, 2017 2018. The following is a summary of performance-based stock option activity under our stock option plans for the years ended December 31, 2021 2020, December 31, 2021 2020: 2021 2020 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 686,001 $ 1.64 737,497 $ 1.64 Exercised (686,001 ) 1.64 (51,496 ) 1.64 Outstanding as of end of year - $ - 686,001 $ 1.64 Stock options exercisable as of year end - $ - 686,001 $ 1.64 No stock compensation expense was recognized during the years ended December 31, 2021, 2020, 2019 December 31, 2021, 2020, 2019 December 31, 2021, 2020, 2019. Restricted stock Service vesting-based restricted stock The following is a summary of service vesting-based restricted stock activity for the years ended December 31, 2021 2020, December 31, 2021 2020: 2021 2020 Shares Wtd. Avg. Grant Date Fair Value Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 930,854 $ 19.31 429,399 $ 13.25 Granted 801,484 47.20 717,267 20.88 Granted in lieu of cash - - 34,154 9.18 Vested (378,502 ) 19.31 (208,858 ) 11.32 Forfeited (141,053 ) 36.95 (41,108 ) 15.47 Non-vested as of year end 1,212,783 $ 37.48 930,854 $ 19.31 On November 4, 2021, one 2023. four December 31, 2022. December 31, 2021 The aggregate fair value of the service vesting-based awards granted during the years ended December 31, 2021, 2020, 2019 December 31, 2021, 2020, 2019 On March 25, 2020, 2019 September 25, 2020 December 31, 2019. We recognized stock compensation expense of $12.7 million, $3.0 million, and $1.2 million related to service vesting-based awards during the years ended December 31, 2021, 2020, 2019, December 31, 2021, Performance-based restricted stock On March 25, 2020, 2020 December 31, 2020. The following is a summary of performance-based restricted stock activity for the years ended December 31, 2021 2020: 2021 2020 Shares Wtd. Avg. Grant Date Fair Value Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year - $ - - $ - Granted - - 82,805 9.18 Vested - - (82,805 ) 9.18 Non-vested as of year end - $ - - $ - We recognized stock compensation expense of zero, $760,000, and zero related to performance-based restricted stock awards for the years ended December 31, 2021, 2020, 2019, December 31, 2021, no The aggregate fair value of the performance-based awards granted during the years ended December 31, 2021, 2020, 2019 December 31, 2021, 2020, 2019 zero zero Market-based restricted stock The following is a summary of market-based restricted stock activity under our stock option plan for the years ended December 31, 2021 2020 December 31, 2021 2020: 2021 2020 Shares Wtd. Avg. Grant Date Fair Value Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 224,774 $ 19.20 123,851 $ 26.99 Granted 152,665 32.50 109,140 10.95 Vested (231,268 ) 26.98 - - Forfeited (6,415 ) 40.65 (8,217 ) 27.02 Non-vested as of year end 139,756 $ 19.86 224,774 $ 19.20 On February 25, 2019 April 1, 2019 February 8, 2021, January 1, 2019 December 31, 2020 20 2 0% December 31, 2020. On March 25, 2020, January 1, 2020 December 31, 2021 20 0% 2 December 31, 2021. On February 8, 2021, January 1, 2021 December 31, 2022 20 0% December 31, 2022. On May 3, 2021, one January 1, 2021 December 31, 2022 20 0% November 2021, December 31, 2021 We recognized stock compensation expense of $1.4 million, $2.1 million, and $1.5 million related to market-based restricted stock awards for the years ended December 31, 2021, 2020, 2019. December 31, 2021, The aggregate fair value of the market-based awards granted during the years ended December 31, 2021, 2020, 2019 December 31, 2021, 2020, 2019 Total stock compensation expense We recorded total stock compensation expense for the years ended December 31, 2021, 2020, 2019, 2021 2020 2019 Research and development costs $ 1,906 $ 1,012 $ 571 Sales and marketing costs 1,788 852 711 General and administrative costs 8,061 3,518 1,584 Cost of revenue 2,201 599 177 Total $ 13,956 $ 5,981 $ 3,043

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	11. Commitments and contingencies Employment agreements We have employment agreements with certain key employees. None may Litigation From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none may not Indemnification As permitted under Delaware law and in accordance with the Company’s bylaws, the Company is required to indemnify its officers and directors for certain errors and occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not December 31, 2021.

Note 12 - Acquisitions

Note 12 - Acquisitions	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Business Combination Disclosure [Text Block]	12. Acquisitions Sexton acquisition General terms and effects On August 9, 2021, On September 1, 2021, December 31, 2021. Total consideration transferred (in thousands, except number of shares and stock price): Merger consideration shares 530,502 BioLife stock price (as of September 1, 2021) $ 60.50 Value of issued shares $ 32,095 plus: Fair value of BioLife’s existing investment in Sexton $ 7,951 less: Net working capital adjustment $ (118 ) Merger Consideration $ 39,928 Transaction costs related to the acquisition are expensed as incurred and are not Fair value of net assets acquired Under the acquisition method of accounting, the assets acquired and liabilities assumed from Sexton were calculated as of the merger date, at their respective fair values, and consolidated with those of BioLife. The gross contractual accounts receivable acquired in the acquisition was $509,000. Of the acquired accounts receivable, $17,000 is estimated to be uncollectable. The fair value calculations required critical estimates, including, but not The table below represents the fair value of the net assets acquired and liabilities assumed, which were recorded as of the merger date (amounts in thousands). Cash $ 1,516 Accounts receivable, net 492 Inventory 1,310 Prepaid expenses and other current assets 670 Property, plant and equipment, net 737 Operating lease right-of-use assets, net 470 Developed technology 4,132 Customer relationships 2,276 Tradenames 2,324 Non-compete agreements 90 Goodwill 28,470 Accounts payable (291 ) Lease liabilities, operating (470 ) Deferred tax liability (1,482 ) Other liabilities (316 ) Fair value of net assets acquired $ 39,928 We recorded a measurement period adjustment in the fourth December 31, 2021 The fair value of Sexton’s identifiable intangible assets and useful lives are as follows (amounts in thousands, except years): Fair Value Useful Life (Years) Developed technology $ 4,132 5 - 9 Customer relationships 2,276 2 Tradenames 2,324 11 Non-compete agreements 90 1 Total identifiable intangible assets $ 8,822 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three not Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not Acquired goodwill The goodwill of $28.5 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recorded is not Global Cooling acquisition General terms and effects On March 19, 2021, On May 3, 2021, Merger consideration The aggregate merger consideration paid pursuant to the GCI Merger Agreement to the GCI Stockholders was 6,646,870 newly issued shares of common stock, provided, however, that the GCI Merger Consideration otherwise payable to GCI Stockholders is subject to the withholding of the GCI Escrow Shares (as defined below) and is subject to reduction for indemnification obligations. The GCI Merger Consideration allocable to one 805, not Total consideration transferred (in thousands, except number of shares, stock price, and consideration percentage): BioLife shares outstanding (as of March 19, 2021) 33,401,359 Merger consideration percentage 19.9 % Merger consideration shares 6,646,870 less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI 10,400 Subtotal 6,636,470 BioLife stock price (as of May 3, 2021) $ 35.07 Value of issued shares $ 232,741 plus: Settlement of BioLife prepaid deposits $ 2,152 plus: Net settlement of BioLife accounts receivable $ 16 Merger Consideration $ 234,909 Transaction costs related to the acquisition are expensed as incurred and are not Escrow shares At the GCI Closing, approximately nine The GCI Escrow Property will be held for a period of up to twenty-four Fair value of net assets acquired Under the acquisition method of accounting, the assets acquired and liabilities assumed from Global Cooling were calculated as of the merger date, at their respective fair values, and consolidated with those of BioLife. The gross contractual accounts receivable acquired in the acquisition was $7.1 million. Of the acquired accounts receivable, $53,000 was estimated to be uncollectable. The fair value calculations required critical estimates, including, but not The table below represents the fair value of the net assets acquired and liabilities assumed, which were recorded as of the merger date (amounts in thousands). Cash $ 43 Accounts receivable, net 7,076 Inventory 15,547 Prepaid expenses and other current assets 639 Property, plant and equipment, net 3,512 Operating lease right-of-use assets, net 1,741 Financing lease right-of-use assets, net 114 Long-term deposits and other assets 4 Developed technology 18,140 Customer relationships 7,020 Tradenames 26,640 Non-compete agreements 1,240 In-process research and development 67,440 Goodwill 137,822 Accounts payable (9,837 ) Line of credit (4,231 ) Lease liabilities, operating (1,880 ) Lease liabilities, financing (114 ) Long-term debt (4,410 ) Deferred tax liability (24,133 ) Other liabilities (7,464 ) Fair value of net assets acquired $ 234,909 We recorded a measurement period adjustment in the fourth December 31, 2021 The fair value of Global Cooling’s identifiable intangible assets and useful lives are as follows (amounts in thousands, except years): Fair Value Useful Life (Years) Developed technology $ 18,140 6 Customer relationships 7,020 12 Tradenames 26,640 15 Non-compete agreements 1,240 4 In-process research and development 67,440 N/A Total identifiable intangible assets $ 120,480 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three not Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not Acquired goodwill The goodwill of $137.8 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recorded is not SciSafe acquisition On September 18, 2020, one hundred October 1, 2020. Consideration transferred The SciSafe Acquisition was accounted for as a purchase of a business under FASB ASC Topic 805, Business Combinations 2021 2024. not Total consideration transferred (in thousands): Cash consideration $ 15,000 Stock consideration 17,916 Contingent consideration 3,663 Working capital adjustment (53 ) Total consideration transferred $ 36,526 Fair value of net assets acquired The table below represents the purchase price allocation to the net assets acquired based on their fair values (amounts in thousands). Cash $ 500 Accounts receivable, net 945 Prepaid expenses and other current assets 31 Property, plant and equipment, net 3,400 Customer relationships 7,420 Tradenames 4,020 Non-compete agreements 660 Goodwill 24,943 Other assets 1,547 Accounts payable (885 ) Deferred tax liability (3,297 ) Other liabilities (2,758 ) Fair value of net assets acquired $ 36,526 On September 30, 2020, The fair value of SciSafe’s identifiable intangible assets and useful lives are as follows (amounts in thousands except years): Fair Value Useful Life (Years) Customer relationships $ 7,420 14 Tradenames 4,020 19 Non-compete agreements 660 4 Total identifiable intangible assets $ 12,100 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three not Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not Indemnification asset In 2020, 805. Acquired goodwill The goodwill of $24.9 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recorded is not Custom Biogenic Systems Acquisition On November 10, 2019, November 12, 2019. In connection with the CBS Acquisition, we paid to CBS (i) a base payment in the amount of $15.0 million, consisting of a cash payment of $11.0 million paid at the closing of the CBS Acquisition, less a cash holdback escrow of $550,000 to satisfy certain indemnification claims, and an aggregate number of shares of our common stock, with an aggregate fair value equal to $4.0 million, less a holdback escrow of shares of Common Stock with an aggregate value equal to $3.0 million to satisfy potential payments related to any product liability claims outstanding as of March 13, 2019, 2020, 2021, 2022, 2023 2024 not 2020 2021 not The CBS Acquisition was accounted for as a purchase of a business under FASB ASC Topic 805, Business Combinations not Total consideration transferred (in thousands): Cash consideration $ 11,000 Stock consideration 4,000 Contingent consideration 856 Total consideration transferred $ 15,856 Fair Value of Net Assets Acquired The table below represents the purchase price allocation to the net assets acquired based on their fair values (amounts in thousands). Accounts receivable, net $ 1,044 Inventory 3,232 Prepaid expenses and other current assets 29 Property, plant and equipment, net 3,615 Customer relationships 560 Tradenames 800 Developed technology 5,430 Goodwill 2,954 Accounts Payable (1,197 ) Other liabilities (611 ) Fair value of net assets acquired $ 15,856 The fair value of CBS’s identifiable intangible assets and weighted average useful lives are as follows (amounts in thousands except years): Fair Value Useful Life (Years) Customer relationships $ 560 6 Tradenames 800 6 Developed technology 5,430 9 Total identifiable intangible assets $ 6,790 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not not Acquired Goodwill The goodwill of $3.0 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. All of the goodwill recorded is deductible for income tax purposes. SAVSU Acquisition On August 8, 2019, not August 8, 2019, Consideration transferred The SAVSU acquisition was accounted for as a purchase of a business under FASB ASC Topic 805, Business Combinations not Under the acquisition method of accounting, the assets acquired and liabilities assumed from SAVSU were recorded as of the acquisition date, at their respective fair values, and consolidated with those of BioLife. The fair value estimates required critical estimates, including, but not Total consideration paid for the acquisition of SAVSU is as follows (amounts in thousands): Stock consideration for 55.6% $ 19,932 This stock consideration plus the fair value of our existing equity investment in SAVSU of $15.9 million results in the total purchase price for accounting purposes of $35.8 million. Fair Value of Net Assets Acquired The table below represents the purchase price allocation to the net assets acquired based on their fair values (amounts in thousands). Cash and cash equivalents $ 1,251 Accounts receivable, net 753 Prepaid expenses and other current assets 19 Property, plant and equipment, net 546 Operating right-of-use asset 233 Assets held for lease 2,441 Customer relationships 80 Tradenames 1,320 Developed technology 10,750 Goodwill 21,037 Accounts Payable and accrued expenses (807 ) Deferred tax liabilities (1,541 ) Other liabilities (232 ) Fair value of net assets acquired $ 35,850 The fair value of SAVSU’s identifiable intangible assets and useful lives are as follows (amounts in thousands except years): Fair Value Useful Life (Years) Customer relationships $ 80 6 Tradenames 1,320 9 Developed technology 10,750 7 - 8 Total identifiable intangible assets $ 12,150 Astero Acquisition On April 1, 2019, In connection with the acquisition, the Company paid (i) a base payment in the amount of $12.5 million consisting of an initial cash payment of $8.0 million at the closing of the transactions, subject to adjustment for working capital, net debt and transaction expenses, and a deferred cash payment that was paid into escrow and subsequently paid to Astero of $4.5 million which was payable upon the earlier of Astero meeting certain product development milestones or one 2019, 2020 2021 2021, three 2019 2021. second 2020 2019 2020, 2021, 2019 2021 not no Consideration transferred The Astero acquisition was accounted for as a purchase of a business under FASB ASC Topic 805, Business Combinations not Total consideration recorded for the acquisition of Astero is as follows (amounts in thousands): Cash consideration $ 12,521 Contingent consideration 1,491 Working capital adjustment (71 ) Total consideration transferred $ 13,941 Fair Value of Net Assets Acquired The table below represents the purchase price allocation to the net assets acquired based on their fair values (amounts in thousands). Cash and cash equivalents $ 11 Accounts receivable, net 154 Inventory 456 Customer relationships 160 Tradenames 470 Developed technology 2,840 In-process research and development 650 Goodwill 9,515 Other assets 99 Accounts Payable (250 ) Other liabilities (164 ) Fair value of net assets acquired $ 13,941 The fair value of Astero’s identifiable intangible assets and useful lives are as follows (amounts in thousands except years): Fair Value Useful Life (Years) Customer relationships $ 160 4 Tradenames 470 9 Developed technology 2,840 5 - 9 In-process research and development 650 N/A Total identifiable intangible assets $ 4,120 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three third Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not not Acquired Goodwill The goodwill of $9.5 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. All but $1.1 million of the goodwill recorded is not Revenue, net income and pro forma presentation The Company recorded revenue from Sexton of $1.8 million and a net loss of $1.0 million from September 1, 2021, December 31, 2021. May 3, 2021, December 31, 2021. October 1, 2020, December 31, 2020. November 12, 2019, December 31, 2019. August 8, 2019, December 31, 2019. April 1, 2019, December 31, 2019. The following unaudited pro forma financial information presents the combined results of operations of Sexton as if the acquisition had occurred on January 1, 2020 2021 2020 (In thousands) (unaudited) (unaudited) Total revenue $ 122,494 $ 50,856 Net (loss) income $ (9,860 ) $ (1,028 ) The following unaudited pro forma financial information presents the combined results of operations of Global Cooling as if the acquisition had occurred on January 1, 2020 2021 2020 (In thousands) (unaudited) (unaudited) Total revenue $ 143,732 $ 87,370 Net income (loss) $ (16,375 ) $ 501 The following unaudited pro forma financial information presents the combined results of operations of SciSafe as if the acquisition had occurred on January 1, 2019 2020 2019 (In thousands) (unaudited) (unaudited) Total revenue $ 52,613 $ 43,221 Net income (loss) $ 1,798 $ (4,528 ) The following unaudited pro forma financial information presents the combined results of operations of CBS as if the acquisition had occurred on January 1, 2018 2019 (In thousands) (unaudited) Total revenue $ 37,001 Net income (loss) $ (493 ) The following unaudited pro forma financial information presents the combined results of operations of SAVSU as if the acquisition had occurred on January 1, 2018 2019 (In thousands) (unaudited) Total revenue $ 28,824 Net income (loss) $ (1,518 ) The following unaudited pro forma financial information presents the combined results of operations of Astero as if the acquisition had occurred on January 1, 2018 2019 (In thousands) (unaudited) Total revenue $ 28,745 Net income (loss) $ (183 )

Note 13 - Consolidated Balance

Note 13 - Consolidated Balance Sheet Detail	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	13. Consolidated balance sheet detail Property and equipment Property and equipment consist of the following as of December 31, 2021 2020: (In thousands) 2021 2020 Property and equipment Leasehold improvements $ 3,840 $ 2,393 Furniture and computer equipment 1,861 902 Manufacturing and other equipment 16,675 10,076 Construction in-progress 2,022 591 Subtotal 24,398 13,962 Less: Accumulated depreciation (6,741 ) (3,842 ) Net property and equipment $ 17,657 $ 10,120 Depreciation expense for property and equipment was $2.9 million, $1.4 million, and $544,000 for the years ended December 31, 2021, 2020, 2019, Accrued expenses and other current liabilities Accrued expenses and other current liabilities consist of the following as of December 31, 2021 2020: (In thousands) 2021 2020 Accrued expenses $ 1,656 $ 472 Accrued taxes 27 112 Accrued compensation 4,351 2,898 Deferred revenue, current 814 931 Other 294 130 Total accrued expenses and other current liabilities $ 7,142 $ 4,543 Warranty reserve liability We reserve estimated exposures on known claims, as well as on a portion of anticipated claims, for product warranty and rework cost, based on historical product liability claims. Claim costs are deducted from the accrual when paid. Factors that could have an impact on the warranty accrual in any given period include the following: changes in manufacturing quality, changes in product costs, changes in product mix and any significant changes in sales volume. A rollforward of our warranty liability is as follows: (In thousands) 2021 2020 Beginning balance $ 212 $ 191 Warranty reserve acquired in the acquisition of Global Cooling 3,353 - Provision for warranties 9,845 137 Settlements of warranty claims (4,012 ) (116 ) Ending Balance $ 9,398 $ 212

Note 14 - Employee Benefit Plan

Note 14 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Defined Contribution Plan [Text Block]	14. Employee benefit plan The Company sponsors 401 may December 31, 2021, 2020, 2019.

Note 15 - Subsequent Events

Note 15 - Subsequent Events	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	15. Subsequent events The Company has evaluated events subsequent to December 31, 2021 no

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions by management affect the Company’s allowance for doubtful accounts, the net realizable value of inventory, fair value of warrant liability, valuation of market based awards, valuations and purchase price allocations related to investments and business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, share-based compensation, contingent consideration from business combinations, and the recoverability of the Company’s deferred tax assets and the related valuation allowance. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation The Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU” acquired on August 8, 2019), November 12, 2019), October 1, 2020), May 3, 2021), September 1, 2021). All long-lived assets are maintained in the United States of America and the Netherlands. Financial statement reclassification Certain classifications on the Consolidated Balance Sheets related to accrued expenses and other current liabilities, debt, current portion, and debt, long-term as of December 31, 2020 no
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation The Company translates balance sheet and income statement items into U.S. dollars. For the Company’s subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using quarterly exchange rates which approximate to average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of accumulated other comprehensive (loss) income in shareholders' equity.
Segment Reporting, Policy [Policy Text Block]	Segment reporting The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one one
Revenue [Policy Text Block]	Revenue recognition To determine revenue recognition for contractual arrangements that we determine are within the scope of Financial Accounting Standards Board (“FASB”) Topic 606, Revenue from Contracts with Customers five five may not 30 90 December 31, 2021, The Company primarily recognizes product revenues, service revenues, and rental revenues. Product revenues are generated from the sale of biopreservation media, ThawSTAR, and freezer products. We recognize product revenue, including shipping and handling charges billed to customers, at a point in time when we transfer control of our products to our customers, which is upon shipment for substantially all transactions. Shipping and handling costs are classified as part of cost of product revenue in the Consolidated Statement of Operations. Service revenues are generated from the storage of biological and pharmaceutical materials. We recognize service revenues over time as services are performed or ratably over the contract term. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606 10 32 18, not one None December 31, 2021. The Company also generates revenue from the leasing of our property, plant, and equipment, operating right-of-use assets, and evo cold chain systems to customers pursuant to service contracts or rental arrangements entered into with the customer. Revenue from these arrangements is not 606 842, Lease The Company enters into various customer service agreements (collectively, “Service Contracts”) with customers to provide biological and pharmaceutical storage services. In certain of these Service Contracts, the property, plant, and equipment or operating right-of-use assets used to store the customer product are used only for the benefit of one may not The Company has assessed its Service Contracts and concluded that certain of the contracts for the storage of customer products met the criteria to be considered a leasing arrangement (“Embedded Leases”), with the Company as the lessor. The specific Service Contracts that met the criteria were those that provided a single customer with the ability to substantially direct the use of the Company’s property, plant, and equipment or operating right-of-use assets. Under ASC 842, None None Embedded Leases may Total bioproduction tools and services revenue for the years ended December 31, 2021, 2020, 2019 Year Ended December 31, (In thousands, except percentages) 2021 2020 2019 Product revenue Freezer and thaw $ 56,620 $ 13,548 $ 3,312 Cell processing 44,965 30,946 23,367 Storage and cold chain services 328 46 165 Service revenue Storage and cold chain services 9,817 1,752 - Rental revenue Storage and cold chain services 7,426 1,795 527 Total revenue $ 119,156 $ 48,087 $ 27,371 ( 1 2021 May 3, 2021 December 31, 2021 September 1, 2021 December 31, 2021. ( 2 2020 October 1, 2020 December 31, 2020. ( 3 2019 April 1, 2019 December 31, 2019; August 8, 2019 December 31, 2019; November 12, 2019 December 31, 2019. The following table includes estimated rental revenue expected to be recognized in the future related to embedded leases as well as estimated service revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting periods. The Company is electing not one 2014 09, Revenue from Contracts with Customers not one December 31, 2021. The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts: Year Ending December 31, (In thousands) 2022 2023 2024 Total Rental revenue $ 10,151 $ 3,748 $ 900 $ 14,799 Service revenue $ 67 $ 31 $ 10 $ 108
Risk and Uncertainties, Policy [Policy Text Block]	Risks and uncertainties COVID- 19 Our domestic and international operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID- 19” December 31, 2021, In the year ended December 31, 2021, 19 not 19 19. The Company reviews capital and amortizing intangible assets (long-lived assets) for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount may not 19 June 30, 2020 19. As a result of the Company’s outlook for revenue from the ThawSTAR and freezer product lines, estimated undiscounted cash flow projections were developed to determine if any impairment of the related intangible assets was warranted. After conducting such review, the Company determined that there was no June 30, 2020. 19 The Company revised the revenue projections for the ThawSTAR and freezer product lines in the second June 30, 2020 December 31, 2020 two no December 31, 2020. June 30, 2020, December 31, 2020 December 31, 2020. The Company may 19 third Any disruption and volatility in the global capital markets as a result of the pandemic may 19 not The ultimate extent to which the COVID- 19 19 On March 27, 2020, On March 11, 2021, 2021” We determined that we met the original eligibility requirements per the guidelines original established by the U.S. federal government as part of the CARES Act for the Pursuant to the Paycheck Protection Program (the “PPP”). As such, on April 20, 2020, April 29, 2020. March 30, 2020, December 31, 2021, December 31, 2021, December 31, 2022. In the SciSafe acquisition, the Company acquired a $295,300 loan from the PPP. The loan incurred interest at 1% and was unsecured. Of the principal borrowed, $284,000 was forgiven in December 2021. not December 2021.
Earnings Per Share, Policy [Policy Text Block]	Earnings per share The Company considers its unexercised warrants and unvested restricted shares, which contain non-forfeitable rights to dividends, participating securities, and includes such participating securities in its computation of earnings per share pursuant to the two two two The following table presents computations of basic and diluted earnings per share under the two Year Ended December 31, (In thousands, except share and earnings per share data) 2021 2020 2019 Basic earnings (loss) per common share Numerator: Net (loss) income $ (7,635 ) $ 2,667 $ (1,657 ) Amount attributable to unvested restricted shares - (135 ) - Amount attributable to warrants outstanding - (82 ) - Net (loss) income allocated to common shareholders (7,635 ) 2,450 (1,657 ) Denominator: Weighted-average common shares issued and outstanding 38,503,944 27,306,258 19,460,299 Basic (loss) earnings per common share $ (0.20 ) $ 0.09 $ (0.09 ) Diluted earnings (loss) per common share Numerator: Net (loss) income $ (7,635 ) $ 2,667 $ (1,657 ) Amount attributable to warrants - (20 ) - Less: gain related to change in fair value of warrants - (3,601 ) - Diluted (loss) earnings per common share (7,635 ) (954 ) (1,657 ) Denominator: Weighted-average common shares issued and outstanding 38,503,944 27,306,258 19,460,299 Diluted (loss) earnings per common share $ (0.20 ) $ (0.03 ) $ (0.09 ) The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: Year Ended December 31, 2021 2020 2019 Stock options and restricted stock awards 1,637,745 2,131,794 2,564,456 Warrants 18,204 1,499,953 2,956,039 Total 1,655,949 3,631,747 5,520,495
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, cash equivalents, and restricted cash Cash equivalents consist primarily of interest-bearing money market accounts. We consider all highly liquid debt instruments purchased with an initial maturity of three may not Restricted cash consists entirely of amounts that will be recovered from escrow in relation to the acquisition of SciSafe. The restricted cash is short term in nature, as the Company anticipates to receive the funds within one The following is a summary of the Company’s cash, cash equivalents, and restricted cash total as presented in the Company’s consolidated statements of cash flows for the years ended December 31, 2021, 2020, 2019. Year Ended December 31, (In thousands) 2021 2020 2019 Cash and cash equivalents $ 69,860 $ 90,403 $ 6,448 Restricted cash 10 53 - Total cash, cash equivalents, and restricted cash $ 69,870 $ 90,456 $ 6,448
Inventory, Policy [Policy Text Block]	Inventories Inventories relate to the Company’s cell and gene therapy products. The Company values biopreservation media inventory at cost or, if lower, net realizable value, using the specific identification method. All other inventory is valued at cost or, if lower, net realizable value, using the first first no
Accounts Receivable [Policy Text Block]	Accounts receivable Accounts receivable consist of short-term amounts due from our customers (generally 30 90 Accounts receivable are stated at principal amount, do not
Investment, Policy [Policy Text Block]	Investments We periodically invest in securities of private companies to promote business and strategic objectives. These investments are measured and recorded as follows: Non-marketable equity securities are equity securities without a readily determinable fair value. As of December 31, 2021, 1 2 December 31, 2020, 1 2 As of December 31, 2021, September 1, 2021. December 31, 2020, not September 2019, December 31, 2021, 2020, 2019, November 2020, 1 2 In November 2020, June 2021, first As of December 31, 2021, no
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment Property and equipment are stated at cost and are depreciated using the straight-line method over estimated useful lives of three ten Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not may December 31, 2021, 2020, 2019.
Assets Held for Rent, Policy [Policy Text Block]	Assets held for rent Assets held for rent are carried at cost less accumulated depreciation. These assets consist of dedicated storage space, evo shippers and related components in production shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. Assets utilized to provide dedicated storage space are depreciated over their applicable useful lives once placed in service. Shippers are depreciated over a useful life of three Our customers rent assets per a rental agreement. Each agreement provides for fixed monthly rent. Rental revenue and fees are recognized over the rental term on a straight-line basis. We retain the ownership of the assets rented. At the end of the rental agreement, the customer returns the asset to the Company. Assets held for rent are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not may no December 31, 2021, 2020, 2019.
Lessee, Leases [Policy Text Block]	Lease accounting We determine if an arrangement is a lease at inception. Where an arrangement is a lease, we determine if it is an operating lease or a finance lease. At lease commencement, we record a lease liability and corresponding right-of-use (“ROU”) asset. Lease liabilities represent the present value of our future lease payments over the expected lease term which includes options to extend or terminate the lease when it is reasonably certain those options will be exercised. The present value of our lease liability is determined using our incremental collateralized borrowing rate at lease inception. ROU assets represent our right to control the use of the leased asset during the lease and are recognized in an amount equal to the lease liability for leases with an initial term greater than 12 We elected to apply the practical expedient for short-term leases and accordingly do not twelve
Standard Product Warranty, Policy [Policy Text Block]	Warranty Our standard warranty terms typically extend between one seven
Income Tax, Policy [Policy Text Block]	Income taxes We account for income taxes using an asset and liability method which generally requires recognition of deferred tax assets and liabilities for the expected future tax effects of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are recognized for the future tax effects of differences between tax bases of assets and liabilities, and financial reporting amounts, based upon enacted tax laws and statutory rates applicable to the periods in which the differences are expected to affect taxable income. We evaluate the likelihood of realization of deferred tax assets and provide an allowance where, in management’s opinion, it is more likely than not not We determine any uncertain tax positions based on a determination of whether and how much of a tax benefit taken in the Company’s tax filings or positions is more likely than not Judgment is applied in the determination of the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. As of December 31, 2021,
Advertising Cost [Policy Text Block]	Advertising Advertising costs are expensed as incurred and totaled $552,000, $167,000, and $43,000 for the years ended December 31, 2021, 2020, 2019,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of risk In the years ended December 31, 2021, 2020, 2019, one No 10% In the year ended December 31, 2019, No 10% December 31, 2021, 2020, 2019. The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Year Ended December 31, Revenue by customers geographic locations 2021 2020 2019 United States 78 % 73 % 69 % Canada 7 % 13 % 16 % Germany 4 % 4 % 3 % Europe, Middle East, Africa (excluding Germany) 10 % 8 % 11 % Other 1 % 2 % 1 % Total revenue 100 % 100 % 100 % The following table represents the Company’s long-lived assets by geographic area as of December 31: (In thousands) 2021 2020 United States $ 40,708 $ 30,389 Netherlands 5,903 - Total $ 46,611 $ 30,389 As of December 31, 2021 2020, two one No 10% As of December 31, 2021 2020, one one No 10%
Research and Development Expense, Policy [Policy Text Block]	Research and development Research and development costs are expensed as incurred.
Share-based Payment Arrangement [Policy Text Block]	Stock-based compensation We measure and record compensation expense using the applicable accounting guidance for share-based payments related to stock options, time-based restricted stock, market-based restricted stock awards and performance-based restricted stock awards granted to our directors and employees. The fair value of stock options, including performance awards, without a market-based condition is determined by using the Black-Scholes option-pricing model. The fair value of restricted stock awards with a market condition is estimated at the date of grant using the Monte Carlo Simulation model. The Black-Scholes and Monte Carlo Simulation valuation models incorporate assumptions as to stock price volatility, the expected life of options or awards, a risk-free interest rate and dividend yield. The fair value of restricted stock, including performance awards, without a market condition is estimated using the current market price of our common stock on the date of grant. We expense stock-based compensation for stock options, restricted stock awards, and performance awards over the requisite service period. For awards with only a service condition, we expense stock-based compensation using the straight-line method over the requisite service period for the entire award. For awards with a market condition, we expense the grant date fair value over the vesting period regardless of the value that the award recipients ultimately receive. We have, from time to time, modified the terms of restricted stock awards awarded to employees. We account for the incremental increase in the fair value over the original award on the date of the modification as an expense for vested awards or over the remaining service (vesting) period for unvested awards. The incremental compensation cost is the excess of the fair value of the modified award on the date of modification over the fair value of the original award immediately before the modification.
Business Combinations Policy [Policy Text Block]	Business combinations The Company accounts for business acquisitions using the acquisition method as required by FASB ASC Topic 805, Business Combinations The Company’s identifiable assets acquired and liabilities, including identified intangible assets, assumed in a business combination are recorded at their acquisition date fair values. The valuation requires management to make significant estimates and assumptions, especially with respect to long-lived and intangible assets. Critical estimates in valuing intangible assets include, but are not ● future expected cash flows, including revenue and expense projections; ● discount rates to determine the present value of recognized assets and liabilities and; ● revenue volatility to determine contingent consideration using option pricing models Goodwill is calculated as the excess of the acquisition price over the fair value of net assets acquired, including the amount assigned to identifiable intangible assets. Acquisition-related costs, including advisory, legal, accounting, valuation, and other costs, are expensed in the periods in which these costs are incurred. The results of operations of an acquired business are included in the consolidated financial statements beginning at the acquisition date. The Company estimates the acquisition date fair value of the acquisition-related contingent consideration using various valuation approaches, including option pricing models, as well as significant unobservable inputs, reflecting the Company’s assessment of the assumptions market participants would use to value these liabilities. The fair value of the contingent consideration is remeasured each reporting period. During the measurement period, which may one
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. Goodwill is not fourth may first not 350, Intangibles Goodwill and Other not 50 not not not not one fourth 2021. no
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible assets Intangible assets with a definite life are amortized over their estimated useful lives using the straight-line method and the amortization expense is recorded within intangible asset amortization in the Consolidated Statements of Operations. If the estimate of a definite-lived intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. Definite-lived intangible assets and their related estimated useful lives are reviewed at least annually to determine if any adverse conditions exist that would indicate the carrying value of these assets may not no may not Indefinite-lived intangibles are carried at the initially recorded fair value less any recognized impairment. In-process research and development (“IPR&D”) is initially capitalized at fair value as an intangible asset with an indefinite life. When the IPR&D project is complete, it is reclassified as a definite-lived intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, a charge would be recorded for the value of the related intangible asset to our Consolidated Statement of Operations in the period it is abandoned. Indefinite-lived intangibles are tested annually for impairment. Impairment assessments are conducted more frequently if certain conditions exist, including a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for the Company’s products or changes in the size of the market for the Company’s products. If impairment indicators are present, the Company determines whether the underlying intangible asset is recoverable through estimated future undiscounted cash flows. If the asset is not one 2021 fourth 2021 no 2021 no
Warrants, Policy [Policy Text Block]	Certain warrants which have features that may Warrants that include cash settlement features are recorded as liabilities at their estimated fair value at the date of issuance and are remeasured at fair value each reporting period with the increase or decrease in fair value recorded in the Consolidated Statements of Operations. The warrants are measured at estimated fair value using the Black Scholes valuation model, which is based, in part, upon inputs for which there is little or no zero December 31, 2021, no December 31: 2020 2019 Risk free interest rate 0.1 % 1.9 % Expected dividend yield 0.0 % 0.0 % Contractual remaining lives 0.2 1.7 Expected volatility 56.8 % 70.3 %
New Accounting Pronouncements, Policy [Policy Text Block]	Recent accounting pronouncements In November 2021, No. 2021 10, Government Assistance (Topic 832 December 15, 2023, In October 2021, No. 2021 08, Business Combinations (Topic 805 Accounting for Contract Assets and Contract Liabilities from Contracts with Customers Revenue from Contracts with Customers (Topic 606 606 2021 08 December 15, 2022, In July 2021, No. 2021 05, Leases (Topic 842 2021 05 840. not 1 842 10 25 2 25 3; 2 one 2021 05 December 15, 2021, not In May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04 2021 04 December 15, 2021, 2021 04 not In August 2020, No. 2020 06, Debt - Debt with Conversion and Other Options (Subtopic 470 20 s Own Equity (Subtopic 815 40 2020 06 2020 06 2020 06 December 15, 2021, no December 15, 2020. not In March 2020, No. 2020 04, Reference Rate Reform (Topic 848 2020 04 January 2021, 2021 01, no December 1, 2022, not In June 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13 November 19, 2019, 2016 13 December 15, 2023,

Note 1 - Organization and Sig_2

Note 1 - Organization and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Revenues By Product Line [Table Text Block]	Year Ended December 31, (In thousands, except percentages) 2021 2020 2019 Product revenue Freezer and thaw $ 56,620 $ 13,548 $ 3,312 Cell processing 44,965 30,946 23,367 Storage and cold chain services 328 46 165 Service revenue Storage and cold chain services 9,817 1,752 - Rental revenue Storage and cold chain services 7,426 1,795 527 Total revenue $ 119,156 $ 48,087 $ 27,371
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	Year Ending December 31, (In thousands) 2022 2023 2024 Total Rental revenue $ 10,151 $ 3,748 $ 900 $ 14,799 Service revenue $ 67 $ 31 $ 10 $ 108
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, (In thousands, except share and earnings per share data) 2021 2020 2019 Basic earnings (loss) per common share Numerator: Net (loss) income $ (7,635 ) $ 2,667 $ (1,657 ) Amount attributable to unvested restricted shares - (135 ) - Amount attributable to warrants outstanding - (82 ) - Net (loss) income allocated to common shareholders (7,635 ) 2,450 (1,657 ) Denominator: Weighted-average common shares issued and outstanding 38,503,944 27,306,258 19,460,299 Basic (loss) earnings per common share $ (0.20 ) $ 0.09 $ (0.09 ) Diluted earnings (loss) per common share Numerator: Net (loss) income $ (7,635 ) $ 2,667 $ (1,657 ) Amount attributable to warrants - (20 ) - Less: gain related to change in fair value of warrants - (3,601 ) - Diluted (loss) earnings per common share (7,635 ) (954 ) (1,657 ) Denominator: Weighted-average common shares issued and outstanding 38,503,944 27,306,258 19,460,299 Diluted (loss) earnings per common share $ (0.20 ) $ (0.03 ) $ (0.09 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2021 2020 2019 Stock options and restricted stock awards 1,637,745 2,131,794 2,564,456 Warrants 18,204 1,499,953 2,956,039 Total 1,655,949 3,631,747 5,520,495
Schedule of Cash and Cash Equivalents [Table Text Block]	Year Ended December 31, (In thousands) 2021 2020 2019 Cash and cash equivalents $ 69,860 $ 90,403 $ 6,448 Restricted cash 10 53 - Total cash, cash equivalents, and restricted cash $ 69,870 $ 90,456 $ 6,448
Revenue from External Customers by Products and Services [Table Text Block]	Year Ended December 31, Revenue by customers geographic locations 2021 2020 2019 United States 78 % 73 % 69 % Canada 7 % 13 % 16 % Germany 4 % 4 % 3 % Europe, Middle East, Africa (excluding Germany) 10 % 8 % 11 % Other 1 % 2 % 1 % Total revenue 100 % 100 % 100 % (In thousands) 2021 2020 United States $ 40,708 $ 30,389 Netherlands 5,903 - Total $ 46,611 $ 30,389
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	2020 2019 Risk free interest rate 0.1 % 1.9 % Expected dividend yield 0.0 % 0.0 % Contractual remaining lives 0.2 1.7 Expected volatility 56.8 % 70.3 %

Note 2 - Fair Value Measureme_2

Note 2 - Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	As of December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 63,873 $ - $ - $ 63,873 Total 63,873 - - 63,873 Liabilities: Contingent consideration - business combinations - - 10,027 10,027 Total $ - $ - $ 10,027 $ 10,027 As of December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 90,403 $ - $ - $ 90,403 Total 90,403 - - 90,403 Liabilities: Contingent consideration - business combinations - - 7,152 7,152 Warrant liability - - 2,780 2,780 Total $ - $ - $ 9,932 $ 9,932
Warrant Liabilities [Member]
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Year Ended December 31, (In thousands) 2021 2020 2019 Beginning balance $ 2,780 $ 39,602 28,516 Exercised warrants (2,901 ) (33,221 ) (1,749 ) Change in fair value recognized in net (loss) income 121 (3,601 ) 12,835 Ending balance $ - $ 2,780 $ 39,602
Contingent Consideration Liabilities [Member]
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Year Ended December 31, (In thousands) 2021 2020 2019 Beginning balance $ 7,152 $ 1,914 - Additions - 3,663 2,347 Change in fair value recognized in net (loss) income 2,875 1,575 50 Payments earned, reclassified to accrued liabilities - - (483 ) Ending balance $ 10,027 $ 7,152 $ 1,914

Note 3 - Inventories (Tables)

Note 3 - Inventories (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	(In thousands) 2021 2020 Raw materials $ 17,252 $ 2,855 Work in progress 5,015 2,006 Finished goods 6,078 6,741 Total $ 28,345 $ 11,602

Note 4 - Assets Held for Rent (

Note 4 - Assets Held for Rent (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Scheduleof Assets Held for Rent [Table Text Block]	(In thousands) 2021 2020 Shippers placed in service $ 5,645 $ 3,171 Fixed assets held for rent 4,040 - Accumulated depreciation (2,272 ) (411 ) Net 7,413 2,760 Shippers and related components in production 2,396 1,945 Total $ 9,809 $ 4,705

Note 5 - Leases (Tables)

Note 5 - Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Lessee, Operating and Finance Lease Term And Discount Rate [Table Text Block]	2021 2020 Weighted average discount rate - operating leases 3.8 % 3.3 % Weighted average discount rate - finance leases 6.1 % 5.7 % Weighted average remaining lease term in years - operating leases 7.8 9.4 Weighted average remaining lease term in years - finance leases 3.0 2.6
Lease, Cost [Table Text Block]	Year Ended December 31, (In thousands) 2021 2020 2019 Operating lease costs $ 2,817 $ 839 $ 612 Short-term lease costs 1,727 277 51 Total operating lease costs 4,544 1,116 663 Variable lease costs 749 357 299 Total lease expense $ 5,293 $ 1,473 $ 962
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	(In thousands) Operating Leases Financing Leases 2022 $ 3,443 $ 171 2023 3,151 171 2024 2,883 101 2025 2,497 37 2026 2,006 2 Thereafter 8,364 - Total lease payments 22,344 482 Less: interest (3,120 ) (42 ) Total present value of lease liabilities $ 19,224 $ 440

Note 6 - Goodwill and Intangi_2

Note 6 - Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Goodwill [Table Text Block]	(In thousands) Goodwill Balance as of December 31, 2019 $ 33,637 Correction of an error related to CBS goodwill (131 ) Goodwill related to SciSafe acquisition 24,943 Balance as of December 31, 2020 58,449 Goodwill related to Global Cooling acquisition 137,822 Goodwill related to Sexton acquisition 28,470 Balance as of December 31, 2021 $ 224,741
Schedule of Finite-Lived Intangible Assets [Table Text Block]	(In thousands, except weighted average useful life) December 31, 2021 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 17,516 $ (1,776 ) $ 15,740 10.3 Tradenames 35,574 (2,306 ) 33,268 13.8 Technology - acquired 41,942 (7,789 ) 34,153 5.9 Non-compete agreements 1,990 (442 ) 1,548 3.0 In-process research and development⁽¹⁾ 67,440 - 67,440 N/A Total intangible assets $ 164,462 $ (12,313 ) $ 152,149 9.8 December 31, 2020 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 8,220 $ (330 ) $ 7,890 12.8 Tradenames 6,610 (508 ) 6,102 14.0 Technology - acquired 19,670 (3,232 ) 16,438 7.1 Non-compete agreements 660 (41 ) 619 3.8 Total intangible assets $ 35,160 $ (4,111 ) $ 31,049 9.7
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	(In thousands) For the Years Ending December 31, Estimated Amortization Expense 2022 $ 11,421 2023 10,951 2024 10,126 2025 9,748 2026 9,346 Thereafter 33,117 Total $ 84,709

Note 7 - Line of Credit and L_2

Note 7 - Line of Credit and Long-term Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Debt [Table Text Block]	December 31, (In thousands) Maturity Date Interest Rate 2021 2020 2022 term loan 1 Sep-24 4.0 % $ 1,750 $ - 2022 term loan 2 Various 4.0 % 2,813 - Insurance premium financing Apr-22 4.0 % 373 - Paycheck Protection Program loan May-22 1.0 % - 295 Freezer equipment loan Dec-25 5.7 % 612 365 Manufacturing equipment loans Oct-25 5.7 % 355 439 Freezer installation loan Various 6.3 % 1,334 156 Other loans Various Various 9 14 Total debt, excluding unamortized debt issuance costs 7,246 1,269 Less: unamortized debt issuance costs (31 ) - Total debt 7,215 1,269 Less: current portion of debt (862 ) (614 ) Total long-term debt $ 6,353 $ 655
Schedule of Maturities of Long-term Debt [Table Text Block]	(In thousands) Amount 2022 $ 862 2023 813 2024 2,294 2025 543 2026 221 Thereafter 2,513 Total debt, excluding unamortized debt issuance costs 7,246 Less: unamortized debt issuance costs (31 ) Total debt $ 7,215

Note 8 - Income Taxes (Tables)

Note 8 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Year Ended December 31, (In thousands) 2021 2020 2019 Domestic $ (27,317 ) $ (597 ) $ (3,198 ) Foreign (436 ) - - Total $ (27,753 ) $ (597 ) $ (3,198 )
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended December 31, (In thousands) 2021 2020 2019 Current: Federal $ - $ - $ - State - 33 - Foreign 9 - - Total current tax provision 9 33 - Deferred: Federal (17,703 ) (3,297 ) (1,541 ) State (2,424 ) - - Foreign - - - Total deferred tax benefit (20,127 ) (3,297 ) (1,541 ) Income tax benefit $ (20,118 ) $ (3,264 ) $ (1,541 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2021 2020 2019 Federal statutory tax 21 % 21 % 21 % State tax, net of federal benefit 7 % 39 % - Stock compensation 38 % 538 % 74 % Sec. 162(m) limitation on executive compensation (12 %) (35 %) (17 %) Fair value change in contingent consideration (2 %) (81 %) - Fair value change in warrant liability - 127 % (82 %) Transaction costs (1 %) (6 %) (4 %) Gain on stock acquisition 5 % - 64 % Tax credits - 12 % 5 % Change in valuation allowance 21 % 35 % (5 %) Book loss on equity method investment - - (5 %) Expired net operating losses (5 %) (100 %) (5 %) Other - (3 %) 1 % Total 72 % 547 % 47 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	(In thousands) 2021 2020 Deferred tax assets related to: Net operating loss carryforwards $ 27,500 $ 12,314 Stock-based compensation 2,066 1,678 Accruals and reserves 2,902 427 Inventory 236 142 Lease liabilities 4,198 2,247 Tax credit carryforward 594 225 Other 318 48 Total deferred tax assets 37,814 17,081 Deferred tax liabilities related to: Intangibles (35,241 ) (5,025 ) Right-of-use assets (4,070 ) (2,261 ) Fair value change in investments (294 ) (287 ) Fixed assets (1,203 ) (959 ) Other - (51 ) Total deferred tax liabilities (40,808 ) (8,583 ) Net deferred tax (liabilities) assets before valuation allowance (2,994 ) 8,498 Less: valuation allowance (2,493 ) (8,498 ) Net deferred tax liabilities $ (5,487 ) $ -
Summary of Valuation Allowance [Table Text Block]	(In thousands) 2021 2020 2019 Balance at January 1 $ 8,498 $ 8,706 $ 8,345 Deferred tax liabilities assumed through acquisitions (8,498 ) (3,297 ) (1,541 ) Charged to income tax expense 2,493 3,089 1,902 Balance at December 31 $ 2,493 $ 8,498 $ 8,706
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	(In thousands) 2021 2020 Balance as of January 1 $ 96 $ - Increase related to prior year tax positions - 36 Increase related to current year tax positions 159 60 Balance as of December 31 $ 255 $ 96

Note 9 - Warrants (Tables)

Note 9 - Warrants (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	2021 2020 2019 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Outstanding at beginning of year 79,100 $ 4.75 3,959,005 $ 4.33 4,080,005 $ 4.35 Exercised (79,100 ) 4.75 (3,879,905 ) 4.33 (121,000 ) 4.75 Outstanding and exercisable at end of year - $ - 79,100 $ 4.75 3,959,005 $ 4.33

Note 10 - Stock-based Compens_2

Note 10 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	2021 2020 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 844,455 $ 2.00 1,570,455 $ 1.96 Exercised (183,064 ) 1.61 - - Forfeited (1,146 ) 5.69 (726,000 ) 1.91 Expired (35,714 ) 1.73 - - Outstanding as of end of year 624,531 $ 2.13 844,455 $ 2.00 Stock options exercisable at year end 624,531 $ 2.13 832,478 $ 1.98 2021 2020 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 686,001 $ 1.64 737,497 $ 1.64 Exercised (686,001 ) 1.64 (51,496 ) 1.64 Outstanding as of end of year - $ - 686,001 $ 1.64 Stock options exercisable as of year end - $ - 686,001 $ 1.64
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Range of Exercise Prices Number Outstanding as of December 31, 2021 Weighted Average Remaining Contractual Life Weighted Average Exercise Price $1.00 - 1.50 26,428 1.05 $ 1.38 $1.51 - 2.00 290,760 3.27 1.87 $2.01 - 2.50 265,775 3.35 2.06 $2.51 - 8.60 41,568 3.75 4.86 624,531 3.24 $ 2.13
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	2021 2020 Shares Wtd. Avg. Grant Date Fair Value Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 930,854 $ 19.31 429,399 $ 13.25 Granted 801,484 47.20 717,267 20.88 Granted in lieu of cash - - 34,154 9.18 Vested (378,502 ) 19.31 (208,858 ) 11.32 Forfeited (141,053 ) 36.95 (41,108 ) 15.47 Non-vested as of year end 1,212,783 $ 37.48 930,854 $ 19.31 2021 2020 Shares Wtd. Avg. Grant Date Fair Value Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year - $ - - $ - Granted - - 82,805 9.18 Vested - - (82,805 ) 9.18 Non-vested as of year end - $ - - $ - 2021 2020 Shares Wtd. Avg. Grant Date Fair Value Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 224,774 $ 19.20 123,851 $ 26.99 Granted 152,665 32.50 109,140 10.95 Vested (231,268 ) 26.98 - - Forfeited (6,415 ) 40.65 (8,217 ) 27.02 Non-vested as of year end 139,756 $ 19.86 224,774 $ 19.20
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	2021 2020 2019 Research and development costs $ 1,906 $ 1,012 $ 571 Sales and marketing costs 1,788 852 711 General and administrative costs 8,061 3,518 1,584 Cost of revenue 2,201 599 177 Total $ 13,956 $ 5,981 $ 3,043

Note 12 - Acquisitions (Tables)

Note 12 - Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Merger consideration shares 530,502 BioLife stock price (as of September 1, 2021) $ 60.50 Value of issued shares $ 32,095 plus: Fair value of BioLife’s existing investment in Sexton $ 7,951 less: Net working capital adjustment $ (118 ) Merger Consideration $ 39,928 BioLife shares outstanding (as of March 19, 2021) 33,401,359 Merger consideration percentage 19.9 % Merger consideration shares 6,646,870 less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI 10,400 Subtotal 6,636,470 BioLife stock price (as of May 3, 2021) $ 35.07 Value of issued shares $ 232,741 plus: Settlement of BioLife prepaid deposits $ 2,152 plus: Net settlement of BioLife accounts receivable $ 16 Merger Consideration $ 234,909 Cash consideration $ 15,000 Stock consideration 17,916 Contingent consideration 3,663 Working capital adjustment (53 ) Total consideration transferred $ 36,526 Cash consideration $ 11,000 Stock consideration 4,000 Contingent consideration 856 Total consideration transferred $ 15,856 Stock consideration for 55.6% $ 19,932 Cash consideration $ 12,521 Contingent consideration 1,491 Working capital adjustment (71 ) Total consideration transferred $ 13,941
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Cash $ 1,516 Accounts receivable, net 492 Inventory 1,310 Prepaid expenses and other current assets 670 Property, plant and equipment, net 737 Operating lease right-of-use assets, net 470 Developed technology 4,132 Customer relationships 2,276 Tradenames 2,324 Non-compete agreements 90 Goodwill 28,470 Accounts payable (291 ) Lease liabilities, operating (470 ) Deferred tax liability (1,482 ) Other liabilities (316 ) Fair value of net assets acquired $ 39,928 Cash $ 43 Accounts receivable, net 7,076 Inventory 15,547 Prepaid expenses and other current assets 639 Property, plant and equipment, net 3,512 Operating lease right-of-use assets, net 1,741 Financing lease right-of-use assets, net 114 Long-term deposits and other assets 4 Developed technology 18,140 Customer relationships 7,020 Tradenames 26,640 Non-compete agreements 1,240 In-process research and development 67,440 Goodwill 137,822 Accounts payable (9,837 ) Line of credit (4,231 ) Lease liabilities, operating (1,880 ) Lease liabilities, financing (114 ) Long-term debt (4,410 ) Deferred tax liability (24,133 ) Other liabilities (7,464 ) Fair value of net assets acquired $ 234,909 Cash $ 500 Accounts receivable, net 945 Prepaid expenses and other current assets 31 Property, plant and equipment, net 3,400 Customer relationships 7,420 Tradenames 4,020 Non-compete agreements 660 Goodwill 24,943 Other assets 1,547 Accounts payable (885 ) Deferred tax liability (3,297 ) Other liabilities (2,758 ) Fair value of net assets acquired $ 36,526 Accounts receivable, net $ 1,044 Inventory 3,232 Prepaid expenses and other current assets 29 Property, plant and equipment, net 3,615 Customer relationships 560 Tradenames 800 Developed technology 5,430 Goodwill 2,954 Accounts Payable (1,197 ) Other liabilities (611 ) Fair value of net assets acquired $ 15,856 Cash and cash equivalents $ 1,251 Accounts receivable, net 753 Prepaid expenses and other current assets 19 Property, plant and equipment, net 546 Operating right-of-use asset 233 Assets held for lease 2,441 Customer relationships 80 Tradenames 1,320 Developed technology 10,750 Goodwill 21,037 Accounts Payable and accrued expenses (807 ) Deferred tax liabilities (1,541 ) Other liabilities (232 ) Fair value of net assets acquired $ 35,850 Cash and cash equivalents $ 11 Accounts receivable, net 154 Inventory 456 Customer relationships 160 Tradenames 470 Developed technology 2,840 In-process research and development 650 Goodwill 9,515 Other assets 99 Accounts Payable (250 ) Other liabilities (164 ) Fair value of net assets acquired $ 13,941
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]	Fair Value Useful Life (Years) Developed technology $ 4,132 5 - 9 Customer relationships 2,276 2 Tradenames 2,324 11 Non-compete agreements 90 1 Total identifiable intangible assets $ 8,822 Fair Value Useful Life (Years) Developed technology $ 18,140 6 Customer relationships 7,020 12 Tradenames 26,640 15 Non-compete agreements 1,240 4 In-process research and development 67,440 N/A Total identifiable intangible assets $ 120,480 Fair Value Useful Life (Years) Customer relationships $ 7,420 14 Tradenames 4,020 19 Non-compete agreements 660 4 Total identifiable intangible assets $ 12,100 Fair Value Useful Life (Years) Customer relationships $ 560 6 Tradenames 800 6 Developed technology 5,430 9 Total identifiable intangible assets $ 6,790 Fair Value Useful Life (Years) Customer relationships $ 80 6 Tradenames 1,320 9 Developed technology 10,750 7 - 8 Total identifiable intangible assets $ 12,150 Fair Value Useful Life (Years) Customer relationships $ 160 4 Tradenames 470 9 Developed technology 2,840 5 - 9 In-process research and development 650 N/A Total identifiable intangible assets $ 4,120
Business Acquisition, Pro Forma Information [Table Text Block]	2021 2020 (In thousands) (unaudited) (unaudited) Total revenue $ 122,494 $ 50,856 Net (loss) income $ (9,860 ) $ (1,028 ) 2021 2020 (In thousands) (unaudited) (unaudited) Total revenue $ 143,732 $ 87,370 Net income (loss) $ (16,375 ) $ 501 2020 2019 (In thousands) (unaudited) (unaudited) Total revenue $ 52,613 $ 43,221 Net income (loss) $ 1,798 $ (4,528 ) 2019 (In thousands) (unaudited) Total revenue $ 37,001 Net income (loss) $ (493 ) 2019 (In thousands) (unaudited) Total revenue $ 28,824 Net income (loss) $ (1,518 ) 2019 (In thousands) (unaudited) Total revenue $ 28,745 Net income (loss) $ (183 )

Note 13 - Consolidated Balanc_2

Note 13 - Consolidated Balance Sheet Detail (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	(In thousands) 2021 2020 Property and equipment Leasehold improvements $ 3,840 $ 2,393 Furniture and computer equipment 1,861 902 Manufacturing and other equipment 16,675 10,076 Construction in-progress 2,022 591 Subtotal 24,398 13,962 Less: Accumulated depreciation (6,741 ) (3,842 ) Net property and equipment $ 17,657 $ 10,120
Schedule of Accrued Liabilities [Table Text Block]	(In thousands) 2021 2020 Accrued expenses $ 1,656 $ 472 Accrued taxes 27 112 Accrued compensation 4,351 2,898 Deferred revenue, current 814 931 Other 294 130 Total accrued expenses and other current liabilities $ 7,142 $ 4,543
Schedule of Product Warranty Liability [Table Text Block]	(In thousands) 2021 2020 Beginning balance $ 212 $ 191 Warranty reserve acquired in the acquisition of Global Cooling 3,353 - Provision for warranties 9,845 137 Settlements of warranty claims (4,012 ) (116 ) Ending Balance $ 9,398 $ 212

Note 1 - Organization and Sig_3

Note 1 - Organization and Significant Accounting Policies (Details Textual)	1 Months Ended		4 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2021USD ($)	Jun. 30, 2020USD ($)	Apr. 20, 2020USD ($)	Sep. 30, 2021USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Nov. 30, 2020USD ($)	Oct. 01, 2020USD ($)	Sep. 30, 2019USD ($)
Number of Reportable Segments					1
Number of Reporting Units					1
Contract with Customer, Liability, Revenue Recognized					$ 671,000
Impairment of Intangible Assets (Excluding Goodwill), Total		$ 0
Business Combination, Contingent Consideration, Liability, Total		$ 388,000				$ 221,000
Deferred Tax Payments, Social Security	$ 297,000				297,000
Payments of Deferred Payments					135,000
Debt Instrument, Decrease, Forgiveness	284,000
Impairment Loss Recognized During Period					0	0	$ 0
Unrecognized Tax Benefits, Ending Balance	255,000				255,000	96,000	0
Advertising Expense					552,000	$ 167,000	$ 43,000
Goodwill, Impairment Loss					$ 0
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Major Customers					1	1	1
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member]
Concentration Risk, Percentage					17.00%	13.00%	15.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Number of Major Customers					2	1
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member]
Concentration Risk, Percentage						17.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk, Percentage					32.00%
Supplier Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Suppliers							1
Supplier Concentration Risk [Member] | Revenue Benchmark [Member] | One Supplier [Member]
Concentration Risk, Percentage							12.00%
Supplier Concentration Risk [Member] | Accounts Payable [Member]
Number of Suppliers				1		1
Supplier Concentration Risk [Member] | Accounts Payable [Member] | One Supplier [Member]
Concentration Risk, Percentage					10.00%	21.00%
Assets Held for Rent [Member]
Property, Plant and Equipment, Useful Life (Year)					3 years
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)					3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)					10 years
Contingent Convertible Preferred Stock [Member]
Debt Securities, Gain (Loss), Total						$ 0
Contingent Convertible Preferred Stock [Member] | Series A-1 and A-2, Preferred Stock [Member]
Equity Securities without Readily Determinable Fair Value, Amount	3,400,000				$ 3,400,000	3,400,000
Contingent Convertible Preferred Stock [Member] | Series E Preferred Stock [Member]
Equity Securities without Readily Determinable Fair Value, Amount	995,000				995,000
Contingent Convertible Preferred Stock [Member] | Series A-2 Preferred Stock [Member]
Equity Securities without Readily Determinable Fair Value, Amount								$ 1,000,000
Contingent Convertible Preferred Stock [Member] | Preferred Stock, Class E [Member]
Contingent Milestone Payment						2,000,000
Contingent Millstone Payment, #1					200,000
Convertible Debt Securities [Member]
Debt Securities, Available-for-sale, Amortized Cost, Total										$ 1,000,000
Debt Securities, Gain (Loss), Total					1,300,000
SciSafe Holdings, Inc [Member]
Business Combination, Contingent Consideration, Liability, Total	$ 9,900,000				9,900,000	6,900,000			$ 3,700,000
Sexton Biotechnologies [Member] | Contingent Convertible Preferred Stock [Member]
Equity Securities without Readily Determinable Fair Value, Amount						1,500,000
PanTHERA Cryosolutions Investment [Member] | Contingent Convertible Preferred Stock [Member] | Series E Preferred Stock [Member]
Equity Securities without Readily Determinable Fair Value, Amount						995,000
PanTHERA Cryosolutions Investment [Member] | Contingent Convertible Preferred Stock [Member] | Preferred Stock, Class E [Member]
Equity Securities without Readily Determinable Fair Value, Amount								$ 995,000
Paycheck Protection Program CARES Act [Member]
Repayments of Debt			$ 2,175,320		$ 0	$ 2,175,000	$ 0
Debt Instrument, Interest Rate, Stated Percentage	1.00%				1.00%
Paycheck Protection Program CARES Act [Member] | SciSafe Holdings, Inc [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt									$ 295,300
Debt Instrument, Interest Rate, Stated Percentage									1.00%

Note 1 - Organization and Sig_4

Note 1 - Organization and Significant Accounting Policies - Revenues By Product Line (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	[1]	Dec. 31, 2020	[2]	Dec. 31, 2019	[3]
Total revenue	$ 119,156		$ 48,087		$ 27,371
Product, Freezer and Thaw [Member]
Total revenue	56,620		13,548		3,312
Product, Cell Processing [Member]
Total revenue	44,965		30,946		23,367
Product, Storage and Cold Chain Services [Member]
Total revenue	328		46		165
Service, Storage and Cold Chain Services [Member]
Total revenue	9,817		1,752		0
Rental, Storage and Cold Chain Services [Member]
Total revenue	$ 7,426		$ 1,795		$ 527
[1]	2021 revenue includes product revenue related to Global Cooling from May 3, 2021 through December 31, 2021 and product revenue related to Sexton from September 1, 2021 through December 31, 2021.
[2]	2020 revenue includes service revenue related to SciSafe from October 1, 2020 through December 31, 2020.
[3]	2019 revenue includes product revenue related to Astero Bio Corporation ("Astero") from April 1, 2019 through December 31, 2019; rental revenue related to SAVSU from August 8, 2019 through December 31, 2019; and product revenue related to CBS from November 12, 2019 through December 31, 2019.

Note 1 - Organization and Sig_5

Note 1 - Organization and Significant Accounting Policies - Summary of Remaining Performance Obligations (Details) $ in Thousands	Dec. 31, 2021USD ($)
Rental Revenue [Member]
Revenue, expected to be recognized in the future	$ 14,799
Service Revenue [Member]
Revenue, expected to be recognized in the future	$ 108

Note 1 - Organization and Sig_6

Note 1 - Organization and Significant Accounting Policies - Summary of Remaining Performance Obligations 2 (Details) $ in Thousands	Dec. 31, 2021USD ($)
Rental Revenue [Member]
Revenue, expected to be recognized in the future	$ 14,799
Service Revenue [Member]
Revenue, expected to be recognized in the future	108
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | Rental Revenue [Member]
Revenue, expected to be recognized in the future	$ 10,151
Revenue, expected to be recognized in the future, period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | Service Revenue [Member]
Revenue, expected to be recognized in the future	$ 67
Revenue, expected to be recognized in the future, period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | Rental Revenue [Member]
Revenue, expected to be recognized in the future	$ 3,748
Revenue, expected to be recognized in the future, period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | Service Revenue [Member]
Revenue, expected to be recognized in the future	$ 31
Revenue, expected to be recognized in the future, period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Rental Revenue [Member]
Revenue, expected to be recognized in the future	$ 900
Revenue, expected to be recognized in the future, period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Service Revenue [Member]
Revenue, expected to be recognized in the future	$ 10
Revenue, expected to be recognized in the future, period (Year)	1 year

Note 1 - Organization and Sig_7

Note 1 - Organization and Significant Accounting Policies - Calculation of Diluted Shares (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net (loss) income	$ (7,635)	$ 2,667	$ (1,657)
Amount attributable to unvested restricted shares	0	(135)	0
Amount attributable to warrants outstanding	0	(82)	0
Net (loss) income allocated to common shareholders	$ (7,635)	$ 2,450	$ (1,657)
Weighted-average common shares issued and outstanding (in shares)	38,503,944	27,306,258	19,460,299
Basic (loss) earnings per common share (in dollars per share)	$ (0.20)	$ 0.09	$ (0.09)
Amount attributable to warrants	$ 0	$ (20)	$ 0
Less: gain related to change in fair value of warrants	0	(3,601)	0
Diluted (loss) earnings per common share	$ (7,635)	$ (954)	$ (1,657)
Diluted (loss) earnings per common share (in dollars per share)	$ (0.20)	$ (0.03)	$ (0.09)

Note 1 - Organization and Sig_8

Note 1 - Organization and Significant Accounting Policies - Anti-dilutive (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Anti-dilutive securities (in shares)	1,655,949	3,631,747	5,520,495
Share-based Payment Arrangement, Option and Restricted Stock Awards [Member]
Anti-dilutive securities (in shares)	1,637,745	2,131,794	2,564,456
Warrant [Member]
Anti-dilutive securities (in shares)	18,204	1,499,953	2,956,039

Note 1 - Organization and Sig_9

Note 1 - Organization and Significant Accounting Policies - Summary of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash and cash equivalents	$ 69,860	$ 90,403	$ 6,448
Restricted cash	10	53	0
Total cash, cash equivalents, and restricted cash	$ 69,870	$ 90,456	$ 6,448

Note 1 - Organization and Si_10

Note 1 - Organization and Significant Accounting Policies - Concentrations Risk by Geographic Locations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Long-Lived Assets	$ 46,611	$ 30,389
Revenue Benchmark [Member] | Geographic Concentration Risk [Member]
Canada	100.00%	100.00%	100.00%
UNITED STATES
Long-Lived Assets	$ 40,708	$ 30,389
UNITED STATES | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]
Canada	7.00%	13.00%	16.00%
NETHERLANDS
Long-Lived Assets	$ 5,903	$ 0
CANADA | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]
Canada	4.00%	4.00%	3.00%
EMEA [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]
Canada	10.00%	8.00%	11.00%
Geographic, Other [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]
Canada	1.00%	2.00%	1.00%

Note 1 - Organization and Si_11

Note 1 - Organization and Significant Accounting Policies - Weighted Average Assumptions (Details)	Dec. 31, 2020	Dec. 31, 2019
Measurement Input, Risk Free Interest Rate [Member]
Warrants and right, measurement input	0.001	0.019
Measurement Input, Expected Dividend Rate [Member]
Warrants and right, measurement input	0	0
Measurement Input, Expected Term [Member]
Warrants and right, measurement input	0.2	1.7
Measurement Input, Price Volatility [Member]
Warrants and right, measurement input	0.568	0.703

Note 2 - Fair Value Measureme_3

Note 2 - Fair Value Measurement (Details Textual)	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Oct. 01, 2020USD ($)	Jun. 30, 2020USD ($)	Nov. 10, 2019	Apr. 01, 2019
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$ 2,875,000	$ 1,575,000	$ 50,000
Business Combination, Contingent Consideration, Liability, Total		221,000			$ 388,000
Astero [Member]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	(81,000)
Business Combination, Contingent Consideration, Liability, Total		81,000
CBS Acquisition [Member]
Business Combination, Contingent Consideration, Liability, Total	140,000
SciSafe Holdings, Inc [Member]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	3,000,000	3,300,000
Business Combination, Contingent Consideration, Liability, Total	$ 9,900,000	$ 6,900,000		$ 3,700,000
Measurement Input, Discount Rate [Member] | Astero [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input							0.175
Measurement Input, Discount Rate [Member] | CBS Acquisition [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.210					0.260
Measurement Input, Discount Rate [Member] | SciSafe Holdings, Inc [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.071			0.045
Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input		0.001	0.019
Measurement Input, Risk Free Interest Rate [Member] | CBS Acquisition [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.0023					0.0174
Measurement Input, Risk Free Interest Rate [Member] | SciSafe Holdings, Inc [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.0085			0.0020
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | Astero [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input							0.0229
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | Astero [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input							0.0241
Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input		0.568	0.703
Measurement Input, Price Volatility [Member] | Astero [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input							0.56
Measurement Input, Price Volatility [Member] | CBS Acquisition [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.63					0.70
Measurement Input, Price Volatility [Member] | Minimum [Member]
Warrants and Rights Outstanding, Measurement Input		0.568
Measurement Input, Price Volatility [Member] | Maximum [Member]
Warrants and Rights Outstanding, Measurement Input		0.846
Measurement Input, Asset Price Volatility [Member] | SciSafe Holdings, Inc [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.72			0.60
Measurement Input, Revenue Volatility [Member] | SciSafe Holdings, Inc [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.27			0.15
Convertible Debt Securities [Member] | Minimum [Member]
Debt Securities, Term (Year)	1 year
Convertible Debt Securities [Member] | Maximum [Member]
Debt Securities, Term (Year)	2 years
Convertible Debt Securities [Member] | Measurement Input, Prepayment Rate [Member]
Debt Securities, Trading, Measurement Input	0.080
Convertible Debt Securities [Member] | Measurement Input, Prepayment Rate [Member] | Minimum [Member]
Debt Securities, Trading, Measurement Input	0.05
Convertible Debt Securities [Member] | Measurement Input, Prepayment Rate [Member] | Maximum [Member]
Debt Securities, Trading, Measurement Input	0.50

Note 2 - Fair Value Measureme_4

Note 2 - Fair Value Measurement - Financial Assets and Liabilities on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Assets	$ 63,873	$ 90,403
Liabilities	10,027	9,932
Contingent Consideration Liabilities [Member]
Liabilities	10,027
Warrant Liabilities [Member]
Liabilities		2,780
Money Market Funds [Member]
Assets	63,873	90,403
Contingent Consideration Liabilities [Member]
Liabilities		7,152
Fair Value, Inputs, Level 1 [Member]
Assets	63,873	90,403
Liabilities	0	0
Fair Value, Inputs, Level 1 [Member] | Contingent Consideration Liabilities [Member]
Liabilities	0
Fair Value, Inputs, Level 1 [Member] | Warrant Liabilities [Member]
Liabilities		0
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Assets	63,873	90,403
Fair Value, Inputs, Level 1 [Member] | Contingent Consideration Liabilities [Member]
Liabilities		0
Fair Value, Inputs, Level 2 [Member]
Assets	0	0
Liabilities	0	0
Fair Value, Inputs, Level 2 [Member] | Contingent Consideration Liabilities [Member]
Liabilities	0
Fair Value, Inputs, Level 2 [Member] | Warrant Liabilities [Member]
Liabilities		0
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Assets	0	0
Fair Value, Inputs, Level 2 [Member] | Contingent Consideration Liabilities [Member]
Liabilities		0
Fair Value, Inputs, Level 3 [Member]
Assets	0	0
Liabilities	10,027	9,932
Fair Value, Inputs, Level 3 [Member] | Contingent Consideration Liabilities [Member]
Liabilities	10,027
Fair Value, Inputs, Level 3 [Member] | Warrant Liabilities [Member]
Liabilities		2,780
Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Assets	$ 0	0
Fair Value, Inputs, Level 3 [Member] | Contingent Consideration Liabilities [Member]
Liabilities		$ 7,152

Note 2 - Fair Value Measureme_5

Note 2 - Fair Value Measurement - Fair Value of Contingent Consideration Using Level 3 Inputs (Details) - Contingent Consideration Liabilities [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Beginning balance	$ 7,152	$ 1,914	$ 0
Additions	0	3,663	2,347
Change in fair value recognized in net (loss) income	(2,875)	(1,575)	(50)
Payments earned, reclassified to accrued liabilities	0	0	(483)
Ending balance	$ 10,027	$ 7,152	$ 1,914

Note 2 - Fair Value Measureme_6

Note 2 - Fair Value Measurement - Fair Value of Warrant Liabilities Using Level 3 Inputs (Details) - Warrant Liabilities [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Beginning balance	$ 2,780	$ 39,602	$ 28,516
Exercised warrants	(2,901)	(33,221)	(1,749)
Change in fair value recognized in net (loss) income	(121)	3,601	(12,835)
Ending balance	$ 0	$ 2,780	$ 39,602

Note 3 - Inventories - Summary

Note 3 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Raw materials	$ 17,252	$ 2,855
Work in progress	5,015	2,006
Finished goods	6,078	6,741
Total	$ 28,345	$ 11,602

Note 4 - Assets Held for Rent_2

Note 4 - Assets Held for Rent (Details Textual) - USD ($)	11 Months Ended	12 Months Ended
	Dec. 13, 2021	Dec. 31, 2020	Dec. 31, 2019
Assets Held for Rent, Depreciation	$ 1,900,000	$ 671,000	$ 174,000

Note 4 - Assets Held for Rent -

Note 4 - Assets Held for Rent - Assets Held for Rent (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Shippers placed in service	$ 5,645	$ 3,171
Fixed assets held for rent	4,040	0
Accumulated depreciation	(2,272)	(411)
Net	7,413	2,760
Shippers and related components in production	2,396	1,945
Total	$ 9,809	$ 4,705

Note 5 - Leases (Details Textua

Note 5 - Leases (Details Textual)	Dec. 31, 2021
Minimum [Member] | Real Estate Lease[Member]
Lessee, Operating Lease, Remaining Lease Term (Year)	1 year
Minimum [Member] | Lease Extensions [Member]
Lessee, Operating Lease, Term of Contract (Year)	1 year
Maximum [Member] | Real Estate Lease[Member]
Lessee, Operating Lease, Remaining Lease Term (Year)	10 years
Maximum [Member] | Lease Extensions [Member]
Lessee, Operating Lease, Term of Contract (Year)	5 years

Note 5 - Leases - Lease Term an

Note 5 - Leases - Lease Term and Discount Rate (Details)	Dec. 31, 2021	Dec. 31, 2020
Weighted average discount rate - operating leases	3.80%	3.30%
Weighted average discount rate - finance leases	6.10%	5.70%
Weighted average remaining lease term in years - operating leases (Year)	7 years 9 months 18 days	9 years 4 months 24 days
Weighted average remaining lease term in years - finance leases (Year)	3 years	2 years 7 months 6 days

Note 5 - Leases - Components of

Note 5 - Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating lease costs	$ 2,817	$ 839	$ 612
Short-term lease costs	1,727	277	51
Total operating lease costs	4,544	1,116	663
Variable lease costs	749	357	299
Total lease expense	$ 5,293	$ 1,473	$ 962

Note 5 - Leases - Maturities of

Note 5 - Leases - Maturities of Lease Liabilities (Details) $ in Thousands	Dec. 31, 2021USD ($)
2022, operating leases	$ 3,443
2022, finance leases	171
2023, operating leases	3,151
2023. finance leases	171
2024, operating leases	2,883
2024, finance leases	101
2025, operating leases	2,497
2025, finance leases	37
2026, operating leases	2,006
2026, finance leases	2
Thereafter, operating leases	8,364
Thereafter, finance leases	0
Total operating lease payments	22,344
Total financing lease payments, finance leases	482
Less: operating lease interest	(3,120)
Less: financing lease interest	(42)
Total present value of operating lease liabilities	19,224
Total present value of financing lease liabilities	$ 440

Note 6 - Goodwill and Intangi_3

Note 6 - Goodwill and Intangible Assets (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill, Purchase Accounting Adjustments		$ (131,000)
Increase (Decrease) in Accounts Payable, Total	$ 2,018,000	(171,000)	$ 768,000
Amortization of Intangible Assets, Total	$ 8,202,000	3,033,000	1,079,000
CBS Acquisition [Member] | Immaterial Error [Member]
Goodwill, Purchase Accounting Adjustments			$ (131,000)
Increase (Decrease) in Accounts Payable, Total		$ (131,000)

Note 6 - Goodwill and Intangi_4

Note 6 - Goodwill and Intangible Assets - Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Balance	$ 58,449	$ 33,637
Correction of an error related to CBS goodwill		(131)
Balance	224,741	58,449
SciSafe Holdings, Inc [Member]
Goodwill related to acquisition		$ 24,943
Global Cooling[Member]
Goodwill related to acquisition	137,822
Sexton Biotechnologies, Inc. [Member]
Goodwill related to acquisition	$ 28,470

Note 6 - Goodwill and Intangi_5

Note 6 - Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Gross Carrying Value			$ 35,160
Accumulated Amortization		$ (12,313)	(4,111)
Net Carrying Value		84,709	31,049
Total intangible assets, gross		164,462
Total intangible assets, net		152,149	$ 31,049
In Process Research and Development [Member]
In-process research and development	[1]	$ 67,440
Weighted Average [Member]
Weighted Average Useful Life (Year)		9 years 9 months 18 days	9 years 8 months 12 days
Customer Relationships [Member]
Gross Carrying Value		$ 17,516	$ 8,220
Accumulated Amortization		(1,776)	(330)
Net Carrying Value		$ 15,740	$ 7,890
Customer Relationships [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)		10 years 3 months 18 days	12 years 9 months 18 days
Trade Names [Member]
Gross Carrying Value		$ 35,574	$ 6,610
Accumulated Amortization		(2,306)	(508)
Net Carrying Value		$ 33,268	$ 6,102
Trade Names [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)		13 years 9 months 18 days	14 years
Technology-Based Intangible Assets [Member]
Gross Carrying Value		$ 41,942	$ 19,670
Accumulated Amortization		(7,789)	(3,232)
Net Carrying Value		$ 34,153	$ 16,438
Technology-Based Intangible Assets [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)		5 years 10 months 24 days	7 years 1 month 6 days
Noncompete Agreements [Member]
Gross Carrying Value		$ 1,990	$ 660
Accumulated Amortization		(442)	(41)
Net Carrying Value		$ 1,548	$ 619
Noncompete Agreements [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)		3 years	3 years 9 months 18 days
[1]	In-process R&D represents the fair value of incomplete research and development that has not yet reached technological feasibility. We will amortize the asset upon technological feasibility.

Note 6 - Goodwill and Intangi_6

Note 6 - Goodwill and Intangible Assets - Future Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
2022	$ 11,421
2023	10,951
2024	10,126
2025	9,748
2026	9,346
Thereafter	33,117
Total	$ 84,709	$ 31,049

Note 7 - Line of Credit and L_3

Note 7 - Line of Credit and Long-term Debt (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Oct. 01, 2021	Dec. 31, 2020
Long-term Debt, Gross	$ 7,246		$ 1,269
Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 5,000
Line of Credit [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	5.50%
Notes Payable [Member]
Long-term Debt, Gross	$ 4,400
Notes Payable [Member] | Advantage Term Note 1 [Member]
Debt Instrument, Face Amount		$ 1,400
Debt Instrument, Interest Rate, Stated Percentage		4.00%
Notes Payable [Member] | Advantage Term Note 2 [Member]
Debt Instrument, Face Amount		$ 1,400
Debt Instrument, Interest Rate, Stated Percentage		4.00%
Notes Payable [Member] | Enhanced Term Note [Member]
Debt Instrument, Face Amount		$ 1,800
Debt Instrument, Interest Rate, Stated Percentage		4.00%
Notes Payable [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	6.50%

Note 7 - Line of Credit and L_4

Note 7 - Line of Credit and Long-term Debt - Long-term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Debt, carrying amount	$ 7,246	$ 1,269
Less: unamortized debt issuance costs	(31)	0
Total debt	7,215	1,269
Less: current portion of debt	(862)	(614)
Total long-term debt	$ 6,353	655
The 2019 Term Loan [Member]
Interest rate	4.00%
Debt, carrying amount	$ 1,750	0
The 2018 Term Loan [Member]
Interest rate	4.00%
Debt, carrying amount	$ 2,813	0
Financed Insurance Premium [Member]
Interest rate	4.00%
Debt, carrying amount	$ 373	0
Paycheck Protection Program CARES Act [Member]
Interest rate	1.00%
Debt, carrying amount	$ 0	295
Freezer Equipment Loan [Member]
Interest rate	5.70%
Debt, carrying amount	$ 612	365
Manufacturing Equipment Loans [Member]
Interest rate	5.70%
Debt, carrying amount	$ 355	439
Freezer Installation Loan [Member]
Interest rate	6.30%
Debt, carrying amount	$ 1,334	156
Other Loans [Member]
Debt, carrying amount	$ 9	$ 14

Note 7 - Line of Credit and L_5

Note 7 - Line of Credit and Long-term Debt - Maturities of Loans Payable (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
2022	$ 862
2023	813
2024	2,294
2025	543
2026	221
Thereafter	2,513
Total debt, excluding unamortized debt issuance costs	7,246	$ 1,269
Less: unamortized debt issuance costs	(31)	0
Total debt	$ 7,215	$ 1,269

Note 8 - Income Taxes (Details

Note 8 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Sep. 01, 2021	May 03, 2021	Oct. 01, 2020	Aug. 07, 2019
Stock-based Compensation, Tax Benefits	$ 10,500	$ 3,200	$ 2,300
Operating Loss Carryforwards, Total	120,600
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	39,500
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	81,100
GCI Acquisition [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities	24,100				$ 24,133
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	8,000
Sexton Acquisition [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities	1,500			$ 1,482
SciSafe Holdings, Inc [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities						$ 3,297
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	3,300
SAVSU [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities							$ 1,541
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	$ 1,500

Note 8 - Income Taxes - Schedul

Note 8 - Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Domestic	$ (27,317)	$ (597)	$ (3,198)
Foreign	(436)	0	0
Total	$ (27,753)	$ (597)	$ (3,198)

Note 8 - Income Taxes - Provisi

Note 8 - Income Taxes - Provision (Benefit) for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Federal	$ 0	$ 0	$ 0
State	0	33	0
Foreign	9	0	0
Total current tax provision	9	33	0
Federal	(17,703)	(3,297)	(1,541)
State	(2,424)	0	0
Foreign	0	0	0
Total deferred tax benefit	(20,127)	(3,297)	(1,541)
Income tax benefit	$ (20,118)	$ (3,264)	$ (1,541)

Note 8 - Income Taxes - Effecti

Note 8 - Income Taxes - Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Federal statutory tax	21.00%	21.00%	21.00%
State tax, net of federal benefit	7.00%	39.00%	0.00%
Stock compensation	38.00%	538.00%	74.00%
Sec. 162(m) limitation on executive compensation	(12.00%)	(35.00%)	(17.00%)
Fair value change in contingent consideration	(2.00%)	(81.00%)	0.00%
Fair value change in warrant liability	0.00%	127.00%	(82.00%)
Transaction costs	(1.00%)	(6.00%)	(4.00%)
Gain on stock acquisition	5.00%	0.00%	64.00%
Tax credits	0.00%	12.00%	5.00%
Change in valuation allowance	21.00%	35.00%	(5.00%)
Book loss on equity method investment	0.00%	0.00%	(5.00%)
Expired net operating losses	(5.00%)	(100.00%)	(5.00%)
Other	0.00%	(3.00%)	1.00%
Total	72.00%	547.00%	47.00%

Note 8 - Income Taxes - Deferre

Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Net operating loss carryforwards	$ 27,500	$ 12,314
Stock-based compensation	2,066	1,678
Accruals and reserves	2,902	427
Inventory	236	142
Lease liabilities	4,198	2,247
Tax credit carryforward	594	225
Other	318	48
Total deferred tax assets	37,814	17,081
Intangibles	(35,241)	(5,025)
Right-of-use assets	(4,070)	(2,261)
Fair value change in investments	(294)	(287)
Fixed assets	(1,203)	(959)
Other	0	(51)
Total deferred tax liabilities	(40,808)	(8,583)
Net deferred tax (liabilities) assets before valuation allowance	(2,994)	8,498
Less: valuation allowance	(2,493)	(8,498)	$ (8,706)	$ (8,345)
Net deferred tax liabilities	$ (5,487)	$ 0

Note 8 - Income Taxes - Change

Note 8 - Income Taxes - Change in Valuation Allowance for Deferred Tax Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Balance at January 1	$ 8,498	$ 8,706	$ 8,345
Deferred tax liabilities assumed through acquisitions	(8,498)	(3,297)	(1,541)
Charged to income tax expense	2,493	3,089	1,902
Balance at December 31	$ 2,493	$ 8,498	$ 8,706

Note 8 - Income Taxes - Summary

Note 8 - Income Taxes - Summary of Income Tax Contingencies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Balance	$ 96,000	$ 0
Increase related to prior year tax positions	0	36,000
Increase related to current year tax positions	159,000	60,000
Balance	$ 255,000	$ 96,000

Note 9 - Warrants (Details Text

Note 9 - Warrants (Details Textual) - $ / shares	Mar. 25, 2021	May 14, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	May 31, 2016	Mar. 31, 2014
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0	$ 4.75	$ 4.33	$ 4.35
Class of Warrant or Right, Exercised During Period (in shares)			79,100	3,879,905	121,000
Warrants to Purchase Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								6,910,283
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 4.75
Warrants in Connection with WAVI Credit Facility [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							550,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 1.75
WAVI Holding AG and Taurus4757 GmbH Warrants [Member]
Stock Issued During Period, Shares, Cashless Warrant Exercises (in shares)		2,747,970
Class of Warrant or Right, Exercised During Period (in shares)		3,871,405	79,100	3,871,405
Warrants Exercised [Member]
Stock Issued During Period, Shares, Cashless Warrant Exercises (in shares)	70,030
Class of Warrant or Right, Exercised During Period (in shares)	79,100

Note 9 - Warrants - Summary of

Note 9 - Warrants - Summary of Warrant Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Outstanding at beginning of year (in shares)	79,100	3,959,005	4,080,005
Outstanding, weighted average exercise price (in dollars per share)	$ 4.75	$ 4.33	$ 4.35
Exercised, number of shares (in shares)	(79,100)	(3,879,905)	(121,000)
Exercised, weighted average exercise price (in dollars per share)	$ 4.75	$ 4.33	$ 4.75
Outstanding, number of shares (in shares)	0	79,100	3,959,005
Outstanding, weighted average exercise price (in dollars per share)	$ 0	$ 4.75	$ 4.33

Note 10 - Stock-based Compens_3

Note 10 - Stock-based Compensation (Details Textual) - USD ($)	May 03, 2021	Feb. 08, 2021	Mar. 25, 2020	Apr. 01, 2019	Feb. 25, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2021	Jul. 31, 2021	Jul. 31, 2020	May 31, 2017	Dec. 31, 2013
Share-based Payment Arrangement, Expense						$ 13,956,000	$ 5,981,000	$ 3,043,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)						3 years 2 months 26 days
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)						624,531	844,455	1,570,455
Share-based Payment Arrangement, Expense						$ 25,000	$ 119,000	$ 370,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value						21,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value						21,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value						$ 6,900,000	$ 13,100,000	$ 7,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						0	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)						3 years 2 months 12 days
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)						0	686,001	737,497
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)						1,212,783	930,854	429,399
Share-based Payment Arrangement, Expense						$ 12,700,000	$ 3,000,000	$ 1,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						801,484	717,267
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value						$ 37,800,000	$ 15,300,000	5,300,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value						$ 15,900,000	$ 4,500,000	$ 1,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)						$ 47.20	$ 20.88
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total						$ 38,900,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)						378,502	208,858
Restricted Stock [Member] | Executive Officer [Member]
Share-based Payment Arrangement, Expense						$ 666,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			34,154
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)			$ 9.18
Performance-based Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)						0	0	0
Share-based Payment Arrangement, Expense						$ 0	$ 760,000	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			82,805			0	82,805
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)			$ 9.18			$ 0	$ 9.18
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Aggregate Fair Value						$ 0	$ 760,000	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested						$ 0	$ 2,300,000	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)						0	82,805
Market-based Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)						139,756	224,774	123,851
Share-based Payment Arrangement, Expense							$ 2,100,000	$ 1,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	6,415	115,634	109,140	29,604	94,247	152,665	109,140
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)						$ 32.50	$ 10.95
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 1,300,000				$ 834,000					$ 1,400,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						1 year
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Aggregate Fair Value						$ 1,800,000	$ 1,200,000	3,300,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested						$ 10,200,000	$ 0	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)		231,268				231,268	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance	68.00%	68.00%	78.00%	69.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	0.20%	0.10%	0.30%	2.50%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	2 years	2 years	2 years	2 years
Market-based Restricted Stock [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards	200.00%	200.00%	200.00%	200.00%
Market-based Restricted Stock [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards	0.00%	0.00%	0.00%
Market-based Restricted Stock [Member] | Executive Officer [Member]
Share-based Payment Arrangement, Expense						$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		30,616
Market-based Restricted Stock First Issuance [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total							$ 3,100,000
Market-based Restricted Stock Second Issuance [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total						$ 1,200,000
The 2013 Performance Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)												6,500,000	5,000,000	4,100,000	3,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)						589,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)						1,400,000
All Other Unapproved Compensation Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)						36,000
Management Performance Bonus Plan 2017 [Member] | Performance Shares [Member]
Share-based Payment Arrangement, Expense						$ 0	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value						$ 27,400,000	$ 1,300,000	$ 3,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						0	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)										1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)										$ 1.64
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)									999,997	999,997

Note 10 - Share-based Compensat

Note 10 - Share-based Compensation - Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Outstanding as of end of year (in dollars per share)	$ 2.13
Share-based Payment Arrangement, Option [Member]
Outstanding (in shares)	844,455	1,570,455
Outstanding, weighted average exercise price (in dollars per share)	$ 2	$ 1.96
Exercised (in shares)	(183,064)	0
Exercised, weighted average exercise price (in dollars per share)	$ 1.61	$ 0
Forfeited (in shares)	(1,146)	(726,000)
Forfeited, weighted average exercise price (in dollars per share)	$ 5.69	$ 1.91
Expired (in shares)	(35,714)	0
Expired, weighted average exercise price (in dollars per share)	$ 1.73	$ 0
Outstanding as of end of year (in shares)	624,531	844,455
Outstanding as of end of year (in dollars per share)	$ 2.13	$ 2
Stock options exercisable at year end (in shares)	624,531	832,478
Options exercisable, weighted average exercise price (in dollars per share)	$ 2.13	$ 1.98
Performance Shares [Member]
Outstanding (in shares)	686,001	737,497
Outstanding, weighted average exercise price (in dollars per share)	$ 1.64	$ 1.64
Exercised (in shares)	(686,001)	(51,496)
Exercised, weighted average exercise price (in dollars per share)	$ 1.64	$ 1.64
Outstanding as of end of year (in shares)	0	686,001
Outstanding as of end of year (in dollars per share)	$ 0	$ 1.64
Stock options exercisable at year end (in shares)	0	686,001
Options exercisable, weighted average exercise price (in dollars per share)	$ 0	$ 1.64

Note 10 - Stock-based Compens_4

Note 10 - Stock-based Compensation - Shares Authorized Under Stock Option Plan (Details)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Number of shares outstanding (in shares) | shares	624,531
Weighted average remaining contractual life (Year)	3 years 2 months 26 days
Weighted average exercise price (in dollars per share)	$ 2.13
Price Range 1 [Member]
Exercise price, lower range (in dollars per share)	1
Exercise price, upper range (in dollars per share)	$ 1.50
Number of shares outstanding (in shares) | shares	26,428
Weighted average remaining contractual life (Year)	1 year 18 days
Weighted average exercise price (in dollars per share)	$ 1.38
Price Range 2 [Member]
Exercise price, lower range (in dollars per share)	1.51
Exercise price, upper range (in dollars per share)	$ 2
Number of shares outstanding (in shares) | shares	290,760
Weighted average remaining contractual life (Year)	3 years 3 months 7 days
Weighted average exercise price (in dollars per share)	$ 1.87
Price Range 3 [Member]
Exercise price, lower range (in dollars per share)	2.01
Exercise price, upper range (in dollars per share)	$ 2.50
Number of shares outstanding (in shares) | shares	265,775
Weighted average remaining contractual life (Year)	3 years 4 months 6 days
Weighted average exercise price (in dollars per share)	$ 2.06
Price Range 4 [Member]
Exercise price, lower range (in dollars per share)	2.51
Exercise price, upper range (in dollars per share)	$ 8.60
Number of shares outstanding (in shares) | shares	41,568
Weighted average remaining contractual life (Year)	3 years 9 months
Weighted average exercise price (in dollars per share)	$ 4.86

Note 10 - Share-based Compens_2

Note 10 - Share-based Compensation - Restricted Stock Activity (Details) - $ / shares	May 03, 2021	Feb. 08, 2021	Mar. 25, 2020	Apr. 01, 2019	Feb. 25, 2019	Dec. 31, 2021	Dec. 31, 2020
Restricted Stock [Member]
Outstanding (in shares)						930,854	429,399
Outstanding at beginning of year, grant date fair value (in dollars per share)						$ 19.31	$ 13.25
Granted (in shares)						801,484	717,267
Granted, grant date fair value (in dollars per share)						$ 47.20	$ 20.88
Granted in lieu of cash (in shares)						0	34,154
Granted in lieu of cash, grant fair value (in dollars per share)						$ 0	$ 9.18
Vested (in shares)						(378,502)	(208,858)
Vested, grant date fair value (in dollars per share)						$ 19.31	$ 11.32
Forfeited (in shares)						(141,053)	(41,108)
Forfeited, grant date fair value (in dollars per share)						$ 36.95	$ 15.47
Outstanding (in shares)						1,212,783	930,854
Outstanding at end of year, grant date fair value (in dollars per share)						$ 37.48	$ 19.31
Performance-based Restricted Stock [Member]
Outstanding (in shares)						0	0
Outstanding at beginning of year, grant date fair value (in dollars per share)						$ 0	$ 0
Granted, grant date fair value (in dollars per share)			$ 9.18			$ 0	$ 9.18
Vested (in shares)						0	(82,805)
Vested, grant date fair value (in dollars per share)						$ 0	$ 9.18
Outstanding (in shares)						0	0
Outstanding at end of year, grant date fair value (in dollars per share)						$ 0	$ 0
Granted (in shares)			82,805			0	82,805
Market-based Restricted Stock [Member]
Outstanding (in shares)						224,774	123,851
Outstanding at beginning of year, grant date fair value (in dollars per share)						$ 19.20	$ 26.99
Granted, grant date fair value (in dollars per share)						$ 32.50	$ 10.95
Vested (in shares)		(231,268)				(231,268)	0
Vested, grant date fair value (in dollars per share)						$ 26.98	$ 0
Forfeited (in shares)						(6,415)	(8,217)
Forfeited, grant date fair value (in dollars per share)						$ 40.65	$ 27.02
Outstanding (in shares)						139,756	224,774
Outstanding at end of year, grant date fair value (in dollars per share)						$ 19.86	$ 19.20
Granted (in shares)	6,415	115,634	109,140	29,604	94,247	152,665	109,140

Note 10 - Share-based Compens_3

Note 10 - Share-based Compensation - Stock Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Stock compensation expense	$ 13,956	$ 5,981	$ 3,043
Research and Development Expense [Member]
Stock compensation expense	1,906	1,012	571
Selling and Marketing Expense [Member]
Stock compensation expense	1,788	852	711
General and Administrative Expense [Member]
Stock compensation expense	8,061	3,518	1,584
Cost of Sales [Member]
Stock compensation expense	$ 2,201	$ 599	$ 177

Note 12 - Acquisitions (Details

Note 12 - Acquisitions (Details Textual) - USD ($)	Sep. 01, 2021	May 03, 2021	Oct. 01, 2020	Sep. 30, 2020	Nov. 12, 2019	Aug. 08, 2019	Apr. 01, 2019	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Nov. 11, 2019	Aug. 07, 2019
Goodwill, Ending Balance								$ 33,637,000	$ 224,741,000	$ 58,449,000	$ 33,637,000	$ 224,741,000	$ 33,637,000	$ 224,741,000	$ 58,449,000	$ 33,637,000
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable														264,718,000	0	0
Payment for Contingent Consideration Liability, Financing Activities														0	483,000	0
Sexton Acquisition [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	530,502
Business Acquisition, Percentage of Equity Issuable Shares Held in Escrow Accounts for Post Closing Claims	10.00%
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net, Total	$ 6,500,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Gross Receivables	509,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Uncollectable Receivables	17,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period									198,000
Goodwill, Ending Balance	28,470,000
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	32,095,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total	39,928,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value	$ 7,951,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual									1,800,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual									(1,000,000)
Sexton Acquisition [Member] | Common Stock Issued to Acquire Participating Holders [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	477,452
Sexton Acquisition [Member] | Common Stock Deposited Into Escrow [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	53,050
GCI Acquisition [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)		6,636,470
Business Acquisition, Percentage of Equity Issuable Shares Held in Escrow Accounts for Post Closing Claims		9.00%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Gross Receivables		$ 7,100,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Uncollectable Receivables		53,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period									$ 607,000
Goodwill, Ending Balance		$ 137,822,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares, Before Adjustments (in shares)		6,646,870
Business Combination, Stock Reduced During Period, Satisfy Note Receivable (in shares)		10,400
Business Combination, Escrow Shares, Period (Month)		24 months
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable		$ 232,741,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total		$ 234,909,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual												39,100,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual												$ (19,600,000)
GCI Acquisition [Member] | One GCI Stockholder [Member]
Business Combination, Stock Reduced During Period, Satisfy Note Receivable (in shares)		10,400
Financing Receivable, after Allowance for Credit Loss, Total		$ 374,000
SciSafe Holdings, Inc [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)			611,683
Goodwill, Ending Balance			$ 24,943,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage			100.00%
Business Acquisition, Share Price (in dollars per share)			$ 29.29
Payments to Acquire Businesses, Gross			$ 15,000,000
Business Acquisition, Amount Held in Escrow			1,500,000
Payments to Acquire Notes Receivable				$ 500,000
Business Combination, Indemnification Assets, Amount as of Acquisition Date			130,000
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable			17,916,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total			36,526,000
Business Combination, Consideration Transferred, Liabilities Incurred			$ 3,663,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual										1,800,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual										$ (416,000)
SciSafe Holdings, Inc [Member] | Maximum [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)			626,000
CBS Acquisition [Member]
Goodwill, Ending Balance																	$ 2,954,000
Payments to Acquire Businesses, Gross					$ 11,000,000
Business Combination, Consideration Transferred, Excluding Contingent Consideration					15,000,000
Business Combination, Acquisition Related Costs					11,000,000
Business Combination, Cash Holdback Escrow to Satisfy Indemnification Claims					550,000
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable					4,000,000									0	0	4,000,000
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Escrow Holdback					3,000,000
Payment for Contingent Consideration Liability, Financing Activities														0	0
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total																	$ 15,856,000
Business Combination, Consideration Transferred, Liabilities Incurred					856,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual								2,100,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual								$ 187,000
CBS Acquisition [Member] | Earning Payments Payable in Each Calendar Year 2020, 2021, 2022, 2023, and 2024 [Member]
Business Combination, Consideration Transferred, Liabilities Incurred					$ 15,000,000
SAVSU [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)						1,100,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net, Total						$ 10,100,000								0	0	10,108,000
Goodwill, Ending Balance																		$ 21,037,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage						44.00%
Business Acquisition, Share Price (in dollars per share)						$ 18.12
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable						$ 19,932,000								$ 0	$ 0	$ 19,932,000
Business Combinations, Number of Shares Acquired (in shares)						8,616
Business Acquisition, Percentage of Voting Interests Acquired						55.60%
Business Combination, Step Acquisition, Equity Interest in Acquiree, including Subsequent Acquisition, Percentage, Total						100.00%
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total						$ 35,800,000												$ 35,850,000
Equity Method Investments						5,800,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value						15,900,000
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination, Total						$ 35,800,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual											692,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual											$ (1,700,000)
Astero [Member]
Goodwill, Ending Balance							$ 9,515,000
Payments to Acquire Businesses, Gross							12,521,000
Business Combination, Acquisition Related Costs							8,000,000
Payment for Contingent Consideration Liability, Financing Activities							483,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total							13,941,000
Payments to Acquire Businesses, Deferred Cash Payment							4,500,000
Business Combination, Consideration Transferred, Liabilities Incurred							1,491,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount							1,100,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual													1,200,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual													$ (1,500,000)
Astero [Member] | Maximum Potential Earnout Payment for 2019, 2020, and 2021 [Member]
Business Combination, Consideration Transferred, Liabilities Incurred							3,500,000
Astero [Member] | Earnout Payment for Calendar Year 2021 [Member]
Business Combination, Consideration Transferred, Liabilities Incurred							$ 5,000,000

Note 12 - Acquisitions - Consid

Note 12 - Acquisitions - Consideration (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 01, 2021	May 03, 2021	Oct. 01, 2020	Nov. 12, 2019	Aug. 08, 2019	Apr. 01, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
BioLife stock price (in dollars per share)	$ 60.50	$ 35.07
Value of issued shares							$ 264,718	$ 0	$ 0
BioLife shares outstanding (as of March 19, 2021) (in shares)		33,401,359
Sexton Acquisition [Member]
Merger consideration shares (in shares)	530,502
Value of issued shares	$ 32,095
plus: Fair value of BioLife’s existing investment in Sexton	7,951
less: Net working capital adjustment	(118)
Merger Consideration	39,928
Working capital adjustment	$ 118
SciSafe Holdings, Inc [Member]
Merger consideration shares (in shares)			611,683
Value of issued shares			$ 17,916
less: Net working capital adjustment			53
Merger Consideration			36,526
Cash consideration			15,000
Contingent consideration			3,663
Working capital adjustment			$ (53)
CBS Acquisition [Member]
Value of issued shares				$ 4,000			0	0	4,000
Merger Consideration				15,856
Cash consideration				11,000
Contingent consideration				$ 856
SAVSU [Member]
Merger consideration shares (in shares)					1,100,000
Value of issued shares					$ 19,932		$ 0	$ 0	$ 19,932
plus: Fair value of BioLife’s existing investment in Sexton					$ 15,900
Astero [Member]
less: Net working capital adjustment						$ 71
Merger Consideration						13,941
Cash consideration						12,521
Contingent consideration						1,491
Working capital adjustment						$ (71)
GCI Acquisition [Member]
Merger consideration shares (in shares)		6,636,470
Value of issued shares		$ 232,741
Merger Consideration		$ 234,909
Merger consideration percentage		19.90%
Merger consideration shares (in shares)		6,646,870
less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI (in shares)		10,400
plus: Settlement of BioLife prepaid deposits		$ 2,152
plus: Net settlement of BioLife accounts receivable		$ 16

Note 12 - Acquisitions - Cons_2

Note 12 - Acquisitions - Consideration (Details) (Parentheticals)	Aug. 08, 2019
SAVSU [Member]
Percentage equity interest purchased	55.60%

Note 12 - Acquisitions - Fair V

Note 12 - Acquisitions - Fair Value of Net Assets Acquired (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 01, 2021	May 03, 2021	Dec. 31, 2020	Oct. 01, 2020	Dec. 31, 2019	Nov. 12, 2019	Nov. 11, 2019	Aug. 08, 2019	Aug. 07, 2019	Apr. 01, 2019
Goodwill	$ 224,741			$ 58,449		$ 33,637
Sexton Acquisition [Member]
Cash		$ 1,516
Accounts receivable, net		492
Inventory		1,310
Prepaid expenses and other current assets		670
Property, plant and equipment, net		737
Operating lease right-of-use assets, net		470
Goodwill		28,470
Accounts payable		(291)
Lease liabilities, operating		(470)
Deferred tax liability	(1,500)	(1,482)
Other liabilities		(316)
Fair value of net assets acquired		39,928
Sexton Acquisition [Member] | Customer Relationships [Member]
Developed technology		2,276
Sexton Acquisition [Member] | Trade Names [Member]
Developed technology		2,324
Sexton Acquisition [Member] | Developed Technology Rights [Member]
Developed technology		4,132
Sexton Acquisition [Member] | Noncompete Agreements [Member]
Developed technology		$ 90
GCI Acquisition [Member]
Cash			$ 43
Accounts receivable, net			7,076
Inventory			15,547
Prepaid expenses and other current assets			639
Property, plant and equipment, net			3,512
Operating lease right-of-use assets, net			1,741
Goodwill			137,822
Accounts payable			(9,837)
Lease liabilities, operating			(1,880)
Deferred tax liability	$ (24,100)		(24,133)
Other liabilities			(7,464)
Fair value of net assets acquired			234,909
Financing lease right-of-use assets, net			114
Long-term deposits and other assets			4
Line of credit			(4,231)
Lease liabilities, financing			(114)
Long-term debt			(4,410)
GCI Acquisition [Member] | Indefinite In Process Research and Development [Member]
In-process research and development			67,440
GCI Acquisition [Member] | Customer Relationships [Member]
Developed technology			7,020
GCI Acquisition [Member] | Trade Names [Member]
Developed technology			26,640
GCI Acquisition [Member] | Developed Technology Rights [Member]
Developed technology			18,140
GCI Acquisition [Member] | Noncompete Agreements [Member]
Developed technology			$ 1,240
SciSafe Holdings, Inc [Member]
Cash					$ 500
Accounts receivable, net					945
Prepaid expenses and other current assets					31
Property, plant and equipment, net					3,400
Developed technology					12,100
Goodwill					24,943
Accounts payable					(885)
Deferred tax liability					(3,297)
Other liabilities					(2,758)
Fair value of net assets acquired					36,526
Other assets					1,547
SciSafe Holdings, Inc [Member] | Customer Relationships [Member]
Developed technology					7,420
SciSafe Holdings, Inc [Member] | Trade Names [Member]
Developed technology					4,020
SciSafe Holdings, Inc [Member] | Noncompete Agreements [Member]
Developed technology					$ 660
CBS Acquisition [Member]
Accounts receivable, net								$ 1,044
Inventory								3,232
Prepaid expenses and other current assets								29
Property, plant and equipment, net								3,615
Developed technology							$ 6,790
Goodwill								2,954
Accounts payable								(1,197)
Other liabilities								(611)
Fair value of net assets acquired								15,856
CBS Acquisition [Member] | Customer Relationships [Member]
Developed technology							560	560
CBS Acquisition [Member] | Trade Names [Member]
Developed technology							800	800
CBS Acquisition [Member] | Developed Technology Rights [Member]
Developed technology							$ 5,430	$ 5,430
SAVSU [Member]
Cash										$ 1,251
Accounts receivable, net										753
Prepaid expenses and other current assets										19
Property, plant and equipment, net										546
Developed technology									$ 12,150
Goodwill										21,037
Accounts payable										(807)
Deferred tax liability										(1,541)
Other liabilities										(232)
Fair value of net assets acquired									35,800	35,850
Operating right-of-use asset										233
Assets held for lease										2,441
SAVSU [Member] | Customer Relationships [Member]
Developed technology									80	80
SAVSU [Member] | Trade Names [Member]
Developed technology									$ 1,320	1,320
SAVSU [Member] | Developed Technology Rights [Member]
Developed technology										$ 10,750
Astero [Member]
Cash											$ 11
Accounts receivable, net											154
Inventory											456
Developed technology											4,120
Goodwill											9,515
Accounts payable											(250)
Other liabilities											(164)
Fair value of net assets acquired											13,941
Other assets											99
Astero [Member] | Customer Relationships [Member]
Developed technology											160
Astero [Member] | Trade Names [Member]
Developed technology											470
Astero [Member] | Developed Technology Rights [Member]
Developed technology											2,840
Astero [Member] | In Process Research and Development [Member]
Developed technology											$ 650

Note 12 - Acquisitions - Acquir

Note 12 - Acquisitions - Acquired Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 01, 2021	May 03, 2021	Oct. 01, 2020	Nov. 12, 2019	Aug. 08, 2019	Apr. 01, 2019	Nov. 11, 2019	Aug. 07, 2019
Total identifiable intangible assets	$ 8,822
Sexton Acquisition [Member] | Developed Technology Rights [Member]
Developed technology	$ 4,132
Sexton Acquisition [Member] | Developed Technology Rights [Member] | Minimum [Member]
Intangible assets, estimated useful life (Year)	5 years
Sexton Acquisition [Member] | Developed Technology Rights [Member] | Maximum [Member]
Intangible assets, estimated useful life (Year)	9 years
Sexton Acquisition [Member] | Customer Relationships [Member]
Developed technology	$ 2,276
Intangible assets, estimated useful life (Year)	2 years
Sexton Acquisition [Member] | Trade Names [Member]
Developed technology	$ 2,324
Intangible assets, estimated useful life (Year)	11 years
Sexton Acquisition [Member] | Noncompete Agreements [Member]
Developed technology	$ 90
Intangible assets, estimated useful life (Year)	1 year
GCI Acquisition [Member]
Total identifiable intangible assets		$ 120,480
GCI Acquisition [Member] | Indefinite In Process Research and Development [Member]
In-process research and development		67,440
GCI Acquisition [Member] | Developed Technology Rights [Member]
Developed technology		$ 18,140
Intangible assets, estimated useful life (Year)		6 years
GCI Acquisition [Member] | Customer Relationships [Member]
Developed technology		$ 7,020
Intangible assets, estimated useful life (Year)		12 years
GCI Acquisition [Member] | Trade Names [Member]
Developed technology		$ 26,640
Intangible assets, estimated useful life (Year)		15 years
GCI Acquisition [Member] | Noncompete Agreements [Member]
Developed technology		$ 1,240
Intangible assets, estimated useful life (Year)		4 years
SciSafe Holdings, Inc [Member]
Developed technology			$ 12,100
SciSafe Holdings, Inc [Member] | Customer Relationships [Member]
Developed technology			$ 7,420
Intangible assets, estimated useful life (Year)			14 years
SciSafe Holdings, Inc [Member] | Trade Names [Member]
Developed technology			$ 4,020
Intangible assets, estimated useful life (Year)			19 years
SciSafe Holdings, Inc [Member] | Noncompete Agreements [Member]
Developed technology			$ 660
Intangible assets, estimated useful life (Year)			4 years
CBS Acquisition [Member]
Developed technology				$ 6,790
CBS Acquisition [Member] | Developed Technology Rights [Member]
Developed technology				$ 5,430			$ 5,430
Intangible assets, estimated useful life (Year)				9 years
CBS Acquisition [Member] | Customer Relationships [Member]
Developed technology				$ 560			560
Intangible assets, estimated useful life (Year)				6 years
CBS Acquisition [Member] | Trade Names [Member]
Developed technology				$ 800			$ 800
Intangible assets, estimated useful life (Year)				6 years
SAVSU [Member]
Developed technology					$ 12,150
SAVSU [Member] | Developed Technology Rights [Member]
Developed technology								$ 10,750
SAVSU [Member] | Customer Relationships [Member]
Developed technology					$ 80			80
Intangible assets, estimated useful life (Year)					6 years
SAVSU [Member] | Trade Names [Member]
Developed technology					$ 1,320			$ 1,320
Intangible assets, estimated useful life (Year)					9 years
SAVSU [Member] | Technology-Based Intangible Assets [Member]
Developed technology					$ 10,750
SAVSU [Member] | Technology-Based Intangible Assets [Member] | Minimum [Member]
Intangible assets, estimated useful life (Year)					7 years
SAVSU [Member] | Technology-Based Intangible Assets [Member] | Maximum [Member]
Intangible assets, estimated useful life (Year)					8 years
Astero [Member]
Developed technology						$ 4,120
Astero [Member] | Developed Technology Rights [Member]
Developed technology						$ 2,840
Astero [Member] | Developed Technology Rights [Member] | Minimum [Member]
Intangible assets, estimated useful life (Year)						5 years
Astero [Member] | Developed Technology Rights [Member] | Maximum [Member]
Intangible assets, estimated useful life (Year)						9 years
Astero [Member] | Customer Relationships [Member]
Developed technology						$ 160
Intangible assets, estimated useful life (Year)						4 years
Astero [Member] | Trade Names [Member]
Developed technology						$ 470
Intangible assets, estimated useful life (Year)						9 years
Astero [Member] | In Process Research and Development [Member]
Developed technology						$ 650

Note 12 - Acquisitions - Pro Fo

Note 12 - Acquisitions - Pro Forma Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Sexton Acquisition [Member]
Total revenue	$ 122,494	$ 50,856
Net income (loss)	(9,860)	(1,028)
GCI Acquisition [Member]
Total revenue	143,732	87,370
Net income (loss)	$ (16,375)	501
SciSafe Holdings, Inc [Member]
Total revenue		52,613	$ 43,221
Net income (loss)		$ 1,798	(4,528)
CBS Acquisition [Member]
Total revenue			37,001
Net income (loss)			(493)
SAVSU [Member]
Total revenue			28,824
Net income (loss)			(1,518)
Astero [Member]
Total revenue			28,745
Net income (loss)			$ (183)

Note 13 - Consolidated Balanc_3

Note 13 - Consolidated Balance Sheet Detail (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Depreciation, Total	$ 2,900,000	$ 1,400,000	$ 544,000

Note 13 - Consolidated Balanc_4

Note 13 - Consolidated Balance Sheet Detail - Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property and equipment	$ 24,398	$ 13,962
Less: Accumulated depreciation	(6,741)	(3,842)
Net property and equipment	17,657	10,120
Leasehold Improvements [Member]
Property and equipment	3,840	2,393
Furniture and Computer Equipment [Member]
Property and equipment	1,861	902
Manufacturing Facility [Member]
Property and equipment	16,675	10,076
Construction in Progress [Member]
Property and equipment	$ 2,022	$ 591

Note 13 - Consolidated Balanc_5

Note 13 - Consolidated Balance Sheet Detail - Accrued Liabilities and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accrued expenses	$ 1,656	$ 472
Accrued taxes	27	112
Accrued compensation	4,351	2,898
Deferred revenue, current	814	931
Other	294	130
Total accrued expenses and other current liabilities	$ 7,142	$ 4,543

Note 13 - Consolidated Balanc_6

Note 13 - Consolidated Balance Sheet Detail - Warranty Reserve Liability (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Beginning balance	$ 212	$ 191
Warranty reserve acquired in the acquisition of Global Cooling	3,353	0
Provision for warranties	9,845	137
Settlements of warranty claims	(4,012)	(116)
Ending Balance	$ 9,398	$ 212

Note 14 - Employee Benefit Pl_2

Note 14 - Employee Benefit Plan (Details Textual) - Defined Contribution Plan, 401 K [Member] - Pension Plan [Member] - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	100.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 822,000	$ 347,000	$ 158,000